tag:blogger.com,1999:blog-81732394239282498152024-03-12T17:50:17.494-07:00Aging Cell - Novel strategies for combating agingThe purpose of this website is to discuss various theories of aging and evaluate several strategies for slowing down the aging processes.
The first strategy to be evaluated is the selective fortification of organic compounds with heavier isotopes of carbon (13C) and hydrogen (deuterium). The isotope effect will create more stable chemical bonds and reduce the effects of oxidative stress on amino acids, lipids and nucleic acids.Unknownnoreply@blogger.comBlogger43125tag:blogger.com,1999:blog-8173239423928249815.post-46926803332183887332019-02-15T08:47:00.001-08:002019-02-15T08:47:54.670-08:00AI Is Rapidly Augmenting Healthcare and Longevity<a href="https://singularityhub.com/2019/02/15/how-ai-is-rapidly-augmenting-healthcare-and-longevity/#.XGbsh_7sc2k.blogger">AI Is Rapidly Augmenting Healthcare and Longevity</a>: AI is about the eat healthcare, resulting in dramatic acceleration of longevity research and an amplification of the human healthspan.Unknownnoreply@blogger.com4tag:blogger.com,1999:blog-8173239423928249815.post-17290143699944526372019-02-15T08:44:00.001-08:002019-02-15T08:44:34.154-08:00AI Is Rapidly Augmenting Healthcare and Longevity<a href="https://singularityhub.com/2019/02/15/how-ai-is-rapidly-augmenting-healthcare-and-longevity/#.XGbsYoCSdeY.blogger">AI Is Rapidly Augmenting Healthcare and Longevity</a>: AI is about the eat healthcare, resulting in dramatic acceleration of longevity research and an amplification of the human healthspan.Unknownnoreply@blogger.com13tag:blogger.com,1999:blog-8173239423928249815.post-20312062086200033202017-05-18T02:17:00.003-07:002017-05-18T02:17:19.455-07:00WuXi Spotlight - Insilico Medicine<iframe allowfullscreen="" frameborder="0" height="270" src="https://www.youtube.com/embed/a2XQfMJNHYs?list=PLeYDrH9AdTK0NhaZL6Qw0KxCzTBAm4YBX" width="480"></iframe>Rochhttp://www.blogger.com/profile/10226480566630388819noreply@blogger.com14tag:blogger.com,1999:blog-8173239423928249815.post-40569896768994675012017-05-18T02:17:00.001-07:002017-05-18T02:17:17.282-07:00WuXi Spotlight - Insilico Medicine<iframe allowfullscreen="" frameborder="0" height="270" src="https://www.youtube.com/embed/a2XQfMJNHYs?list=PLeYDrH9AdTK0NhaZL6Qw0KxCzTBAm4YBX" width="480"></iframe>Rochhttp://www.blogger.com/profile/10226480566630388819noreply@blogger.com4tag:blogger.com,1999:blog-8173239423928249815.post-75890123637075941682016-12-23T13:08:00.001-08:002016-12-23T13:08:49.782-08:00Aging.AI 2.0 launches to provide a biomarker of aging with less parameters<b>Aging.AI 2.0 is now available for testing. Please use your recent blood test to guess your age. </b><br />
<br />
The system is available at http://www.Aging.AI<br />
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="https://media.eurekalert.org/multimedia_prod/pub/web/126472_web.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="320" src="https://media.eurekalert.org/multimedia_prod/pub/web/126472_web.jpg" width="320" /></a></div>
<br />
<br />
Citation (full text):<br />
<div dir="ltr" style="line-height: 1.38; margin-bottom: 0pt; margin-top: 0pt;">
<span style="background-color: white; color: #222222; font-family: "arial"; font-size: 13.3333px; vertical-align: baseline; white-space: pre-wrap;">Putin, Evgeny, Polina Mamoshina, Alexander Aliper, Mikhail Korzinkin, Alexey Moskalev, Alexey Kolosov, Alexander Ostrovskiy, Charles Cantor, Jan Vijg, and Alex Zhavoronkov. "Deep biomarkers of human aging: Application of deep neural networks to biomarker development." </span><span style="background-color: white; color: #222222; font-family: "arial"; font-size: 13.3333px; font-style: italic; vertical-align: baseline; white-space: pre-wrap;">Aging</span><span style="background-color: white; color: #222222; font-family: "arial"; font-size: 13.3333px; vertical-align: baseline; white-space: pre-wrap;"> 8, no. 5 (2016): 1-021.</span></div>
<span id="docs-internal-guid-99f40240-2d7f-4220-fa46-eae07bdfb3a4"><span style="background-color: white; color: #222222; font-family: "arial"; font-size: 13.3333px; vertical-align: baseline; white-space: pre-wrap;">https://www.ncbi.nlm.nih.gov/pubmed/27191382</span></span><br />
<span style="background-color: white; font-size: 13.3333px; vertical-align: baseline; white-space: pre-wrap;"><span style="color: #222222; font-family: "arial";">http://www.aging-us.com/article/SzdNR3HCatAdyvwPR/text</span></span><br />
<span style="background-color: white; font-size: 13.3333px; vertical-align: baseline; white-space: pre-wrap;"><span style="color: #222222; font-family: "arial";"><br /></span></span>Unknownnoreply@blogger.com10tag:blogger.com,1999:blog-8173239423928249815.post-54614362105431922352016-08-14T01:05:00.000-07:002016-08-14T01:05:17.815-07:00"Regeneration Intelligence" For Diagnosis of Lung and Liver fibrosis and Glaucoma<div style="text-align: justify;">
Collaboration of Insilico Inc. with Atlas Regeneration Inc, Vision Genomic Inc and Howard University has given two high impact papers to explain use of newly developed Regeneration Intelligence tool for the identification of perturbation in pathways of lung and liver fibrosis and glaucoma. It can be used as diagnosis tool for the fibrosis that is often mis-diagnosed.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<b>A) Lung and Liver Fibrosis</b></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Fibrosis is a age related condition that is marked by the accumulation of extracellular matrix that occurs in wide range organs. This leads to changes in the structural and functional properties of organ that leads to pathological conditions. Lungs and liver are the most commonly affected by fibrotic situation leading to development of idiopathic pulmonary fibrosis (IPF) and hepatic fibrosis.<br />
<br />
<table cellpadding="0" cellspacing="0" class="tr-caption-container" style="float: left; margin-right: 1em; text-align: left;"><tbody>
<tr><td style="text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgg8PKQMgkRJMWIAEvy43OdLYJChvTV9niWFIo-MTygl0NSPUCB2DlsRhuOzyHUIbwcgZUf5qbBgHyrvDNlRsUOREDHt1T1mJmrdoemWQRaPAa9M_IBBusX9FnETdA1lkBNX5rLbIjYSCk/s1600/kccy-15-13-1152435-g001.jpg" imageanchor="1" style="clear: left; margin-bottom: 1em; margin-left: auto; margin-right: auto; text-align: justify;"><img border="0" height="196" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgg8PKQMgkRJMWIAEvy43OdLYJChvTV9niWFIo-MTygl0NSPUCB2DlsRhuOzyHUIbwcgZUf5qbBgHyrvDNlRsUOREDHt1T1mJmrdoemWQRaPAa9M_IBBusX9FnETdA1lkBNX5rLbIjYSCk/s200/kccy-15-13-1152435-g001.jpg" width="200" /></a></td></tr>
<tr><td class="tr-caption" style="text-align: center;">Figure 1 a - c</td></tr>
</tbody></table>
<div style="text-align: justify;">
The figure 1 a) & b) shows venn diagram of common pathway up-regulated and down regulated respectively for lung and liver fibrosis c) venn diagram d) PAS values for 20 common signaling pathway of lung and liver fibrosis</div>
<br />
By their new <b>Regeneration Intelligence algorithm</b> they were able to pin down to TFG-beta, IL6 and ILK signaling pathways, which were found to be conserved in fibro-genesis. The software provides a validated mathematical frame work for assessment of signaling pathway alteration that drives the fibrosis in organs like lungs and liver.<br />
<br />
This work supports a theory that conserved signaling elements may shared by various fibrotic organs. It provides a new evidence that evolutionary conserved pathways can be used as therapeutic drug targets. The work was highlighted in <a href="http://www.eurekalert.org/pub_releases/2016-07/imi-psi072916.php" target="_blank">Eureka Alert Science Magazine</a> and <a href="http://www.business-standard.com/article/news-ians/fibrosis-plays-a-role-in-ageing-116073100635_1.html" target="_blank">Business Standard news letter</a>. <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4957589/" target="_blank">The scientific paper can be downloaded from this here</a>.<br />
<br />
<b>B) Glaucoma </b></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Glaucoma is also kind of fibrotic condition. Primary open angle glaucoma (POAG) is most common form of glaucoma that is characterised by free aqueous humor (AH) outflow and logging between iris and cornea that do not get drained from trabecular meshwork (TM) due to clogging of the channels. This causes damaging effect on the mesh like Lamina Cribrosa (LC) through which optic nerve bypass. They have used a software suite, AMD medicine to understand the molecular pathway that causes the accumulation of AH and prevention of its outflow by carrying out intracellular signalling pathway activation (SAP). <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4934076/" style="text-align: center;" target="_blank">Accepted paper can be found here</a></div>
<div style="text-align: justify;">
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEh9wzD03PP8VEASWDisgqV-58sdF_prn2cDSeHl_Ep8ydvWWaaqZx-GK_IyyXqDJvDrqgCdGzHtPaTZUdCgKXrBHaTrRyllbcT_UaRS9v1-dwOA5ogoCWx4b6PZ8YemAJj4IFZJaQL9iyM/s1600/kccy-15-12-1170261-g005.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="242" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEh9wzD03PP8VEASWDisgqV-58sdF_prn2cDSeHl_Ep8ydvWWaaqZx-GK_IyyXqDJvDrqgCdGzHtPaTZUdCgKXrBHaTrRyllbcT_UaRS9v1-dwOA5ogoCWx4b6PZ8YemAJj4IFZJaQL9iyM/s400/kccy-15-12-1170261-g005.jpg" width="400" /></a></div>
<b><br /></b>
<b>Figure 2: </b> It shows the pathology of formation of glaucoma due to increase intra ocular pressure due to blockage in the removal of AH. <b>A) </b>shows TM and optical nerve head containing TC. <b>B)</b> shows TM located between cornea and iris. It shows that AH produced by ciliary body is moved towards anterior end shown by arrows and expelled into schlemm's canal via TM. <b>C)</b> shows flow of AH into schlemm's canal through juxtacanaliular tissue. AH outflow is blocked due to clogging in TM leads to increase in intra ocular pressure.<b> D)</b> Optic nerve head containing axon of RGC and lamina cribrosa structure. <b>E)</b> shows morphology of collagen fibres of lamina cribrosa.<b> F) </b>SEM trabecular meshwork and <b>G)</b> SEM of lamina cribrosa. <br />
<br />
They have found that TGF-beta causes activation of pro-fibrotic pathway in TM and LC. This activated pro-fibrotic pathway causes extracellular matrix re-modelling in TM and LC. This makes TM less efficient in draining the AH. This causes LC more susceptible to damage due to increase intra ocular pressure caused because of increased AH. They propose molecular pathways that could be used for developing therapeutic intervention against glaucoma. The significance of the finding was recently discussed <b><a href="http://www.eurekalert.org/pub_releases/2016-07/imi-psi072916.php" target="_blank">Eureka Alert Science Magazine</a> and <a href="http://www.news-medical.net/news/20160730/Scientists-use-Regeneration-Intelligence-to-assess-perturbation-status-of-many-signaling-pathways.aspx" target="_blank">Medical News</a></b>. These two papers shows a proof principle that there are some common age related signalling pathways that are shared by organs. Regeneration Intelligence based mathematical frame work gives an opportunity to explore this tool towards study of common signatures for age related fibrosis in other organs of human body. This may give us an opportunity to design an effective therapeutic strategy to fight age related disease like fibrosis.</div>
Rochhttp://www.blogger.com/profile/10226480566630388819noreply@blogger.com7tag:blogger.com,1999:blog-8173239423928249815.post-63011471300764255642016-07-15T20:44:00.001-07:002016-07-15T21:54:39.057-07:00Companies Coming Together To Fight Ageing<h2>
Mergers Can Solve Ageing Problem!!<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgOtquAbRIKyWFJChciytSr_9eSOYaIrnVR3-NuPYUkMVAbLc1QufEqewOpFy3Z_gIu1VAtC3FzQ0eoM6XKEP5GVBNtDQ1YprMTZSYJ8R_AhMa-xasuR__eEkW9gdjAN1AUwkC8Ewhu9JA/s1600/companies.png" imageanchor="1" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"><img border="0" height="271" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgOtquAbRIKyWFJChciytSr_9eSOYaIrnVR3-NuPYUkMVAbLc1QufEqewOpFy3Z_gIu1VAtC3FzQ0eoM6XKEP5GVBNtDQ1YprMTZSYJ8R_AhMa-xasuR__eEkW9gdjAN1AUwkC8Ewhu9JA/s400/companies.png" width="400" /></a></div>
</h2>
<b><br /></b>
Merger of scientific brain may help to find out newer ways to fight ageing.<br />
<h3>
<a href="http://www.lifeextension.com/Welcome" target="_blank">A. LifeExtension</a></h3>
<div>
<div style="text-align: justify;">
Life extension is currently a 35 billion dollar supplement producing company. The company has nearly 20 years history of developing innovative products to fight ageing and age related diseases. History of the company in antiaging research:<br />
<br /></div>
</div>
<div>
<div style="text-align: justify;">
* 1983: Their research showed that low doses of aspirin may help in reducing the incidence of heart attack. They also recommended the use of co enzyme Q10 (CoQ10) as an anti ageing nutrient.</div>
</div>
<div>
<div style="text-align: justify;">
* 1992: Introduction of melatonin in America for anti-ageing therapy</div>
</div>
<div>
<div style="text-align: justify;">
* 1996: Published research to check the level of fibrinogen as risk factor for cardiovascular disease</div>
<div style="text-align: justify;">
*1997: Introduced s-adenosyl methionine (SAM) for alleviating depression, arthritis and liver diseases.<br />
*2000: They found that taking hight level of antioxidants for extended period of time helps in reducing the atherosclerosis<br />
*2006: A relatively better form of CoQ10 that is absorbed relatively better than parent product.<br />
*2010: They stressed that pomogranate, resveratrol and quercetin may help in fighting ageing.<br />
*2012: Introduced a product featuring oleuropein that helps in modulation of arterial resistance and stiffness.<br />
*2013: Introduction of supplements that consists of polyphenols gastrodin that works as brain shield against antioxidants, inflammatory and excitatory damage.<br />
*2014: Introduction of formulation that supports adenosine monophosphate activated protein kinase (AMPK)<br />
*2015: Introduction of pollen extract that promote prostate function and healthy urination.</div>
<h2>
<iframe allowfullscreen="" class="YOUTUBE-iframe-video" data-thumbnail-src="https://i.ytimg.com/vi/Gt0IqXyxnXk/0.jpg" frameborder="0" height="266" src="https://www.youtube.com/embed/Gt0IqXyxnXk?feature=player_embedded" style="clear: left; float: left;" width="320"></iframe><span style="background-color: white;"><br /></span></h2>
<h2>
<span style="background-color: white;"><br /></span></h2>
<h2>
<span style="background-color: white;"><br /></span></h2>
<h2>
<span style="background-color: white;"><br /></span></h2>
<h2>
<span style="background-color: white;"><br /></span></h2>
<h2>
</h2>
<div>
<br /></div>
<h2>
B. <a href="http://insilicomedicine.com/" target="_blank">Insilico Inc</a> Collaboration With Life Extension</h2>
<span style="text-align: justify;">In silico Inc. has been a major point of attraction in my blogs about ageing. The company is being operated from John Hopkins University. They are a group of computational biogenrontologists who believe that they can cure ageing. The group is extensively working in the field of developing computational models for coming closer and closer to fight ageing.</span><br />
<div style="text-align: justify;">
<br />
Insilico Inc. joins hands with larger number of pharmaceutical company in the pursuit of slowing down the ageing process. Recently they have collaborated with Life Extension (a supplement producing company) with the aim of slowing that ageing process. With the long history of Life extension and progressive nature of Insilico Inc. there is a possibility of introduction of range of geroprotectors that may slow down the ageing process early next year (News Published: a) <a href="http://www.telegraph.co.uk/good-news/2016/06/20/how-to-live-to-100-meet-the-scientist-who-believes-he-can-cure-ageing/">http://www.telegraph.co.uk/good-news/2016/06/20/how-to-live-to-100-meet-the-scientist-who-believes-he-can-cure-ageing/</a> and b) <a href="http://www.prnewswire.com/news-releases/life-extension-joins-with-insilico-medicine-to-develop-advanced-anti-aging-technologies-utilizing-artificial-intelligence-300280735.html">http://www.prnewswire.com/news-releases/life-extension-joins-with-insilico-medicine-to-develop-advanced-anti-aging-technologies-utilizing-artificial-intelligence-300280735.html</a>)<br />
<h2>
C. In Silico Inc. Collaboration With <a href="http://www.biotimeinc.com/" target="_blank">BioTime Inc</a>.</h2>
<iframe allowfullscreen="" class="YOUTUBE-iframe-video" data-thumbnail-src="https://i.ytimg.com/vi/MbgZSDqPe78/0.jpg" frameborder="0" height="266" src="https://www.youtube.com/embed/MbgZSDqPe78?feature=player_embedded" width="320"></iframe>BioTime Inc is a clinical stage regenerative medicine company that was focuses on the development of newer technologies fight ageing via. pluripotent cells. Unlike other pharmaceutical products that works on the basis of molecular drug targets, pathways and genetic expression profiles; BioTime's approach has been at the cellular level. Where the pluripotent cells can replace the damaged cells to provide therapeutic output. The simple it sounds the more complex it is. Regeneration of tissue from embryonic cells and formation of scar tissue for an adult for therapeutic purpose is extremely complex process. Hence, in June 2016 they collaborated with Insilico Inc. to study this complex process via machine learning method. The idea of this collaboration was combine the technological advances of AI by Insilico Inc. and pluripotent cells based therapy by BioTime to produce next generation therapeutic solutions for cancer and age related disease..<br />
<br />
In this context, AI was developed by BioTime Inc called as <a href="http://embryonic.ai/">Embryonic.AI</a>. It is transcriptomic based classifier that can be used for searching the queries to check how much close is the sample to the embryonic state. Embryonic. AI is basically a deep learning machine that is validated based on the thousands of samples that representative of the human embryonic stem cells. This includes human embryonic stem cells (ESC), induced pluripotent stem cells (IPSC), embryonic progenitor cells (EPC), adult stem cells (ASC) and adult cells (AC). Once the query it provided to the AI it gives out score that acts as a measure of the development stage of cells. Where ES=1 represents embryonic state and ES=0 represents adult cellular states. Here is link to the <a href="http://embryonic.ai/faq" target="_blank">FAQs </a>that can be used for more details<br />
<br />
<br /></div>
</div>
Rochhttp://www.blogger.com/profile/10226480566630388819noreply@blogger.com3tag:blogger.com,1999:blog-8173239423928249815.post-79477688402285969272016-05-30T01:06:00.000-07:002016-05-30T01:06:50.251-07:00Deep Neural Networks: New Drug Discovery To Repurposing<div style="text-align: justify;">
Yet another exciting paper published by InSilico Inc in addition to their work on developing the model based on Deep Neural Networks on the prediction of human age... <a href="https://www.ncbi.nlm.nih.gov/pubmed/27191382" target="_blank">(paper can be downloaded here)</a>. <a href="http://www.agingbiomarkers.com/2016/05/deep-neural-network-for-prediction-of.html" target="_blank">Summary of the work can be seen in our previous blog posts here</a></div>
<div>
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhIh2UoSnBCGE0l9mlJLhLg5F9g9GRhouMQnNo3Bt0UT0F1vqHqdKF6oZ7WnHrHtwjSxysUUpsbbTpe7FKQxKlN5cA8ZMoKcoeL63wg9iengOOgpz0ve5R44m-7unvakRgzkyRyuYoWZn4/s1600/AI.jpg" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em; text-align: justify;"><img border="0" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhIh2UoSnBCGE0l9mlJLhLg5F9g9GRhouMQnNo3Bt0UT0F1vqHqdKF6oZ7WnHrHtwjSxysUUpsbbTpe7FKQxKlN5cA8ZMoKcoeL63wg9iengOOgpz0ve5R44m-7unvakRgzkyRyuYoWZn4/s1600/AI.jpg" /></a><br />
<div style="text-align: justify;">
<br /></div>
</div>
<div>
<div style="text-align: justify;">
This month paper was published about the use of Deep Neural Networks (DNN) in new drug discovery and repurposing using transcriptomic data.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
The paper got recently published in Molecular Pharmaceutics....... <a href="http://pubs.acs.org/doi/abs/10.1021/acs.molpharmaceut.6b00248" target="_blank"><i>can be downloaded from here</i></a></div>
<div style="text-align: justify;">
<i><br /></i></div>
<div style="text-align: justify;">
<i>Deep learning is an artificial intelligence (AI). It utilises higher level or multilayer of the neuron to model the high level of abstraction of data. </i></div>
<div style="text-align: justify;">
<br /></div>
<div>
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEj_R7uYOl02C1h9agN4l7G-oZNU3vTWqXOCLjF240-mwlal8GmErGXgQBGul0MouAynZDEaGlgiMKAx2ogzYLThp1Rrk98xgIsFMhwh2mAx2mm6gIHGOFAe8jQSFxW7x9w_YwKIIwpcja0/s1600/Screen+Shot+2016-05-29+at+3.44.42+PM.png" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em; text-align: justify;"><img border="0" height="131" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEj_R7uYOl02C1h9agN4l7G-oZNU3vTWqXOCLjF240-mwlal8GmErGXgQBGul0MouAynZDEaGlgiMKAx2ogzYLThp1Rrk98xgIsFMhwh2mAx2mm6gIHGOFAe8jQSFxW7x9w_YwKIIwpcja0/s400/Screen+Shot+2016-05-29+at+3.44.42+PM.png" width="400" /></a><br />
<div style="text-align: justify;">
The paper published clearly shows that AI neural network was able to predict the therapeutic use of a large number of medicine depending on gene expression data that is obtained from high-throughput experiments on human cell lines.</div>
</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
The significance of the work got recently published in <a href="http://www.eurekalert.org/pub_releases/2016-05/imi-dla052416.php" target="_blank">Eureka News Alert</a></div>
<div style="text-align: justify;">
<br /></div>
<table cellpadding="0" cellspacing="0" class="tr-caption-container" style="float: right; margin-left: 1em; text-align: right;"><tbody>
<tr><td style="text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhRWjOfFccPlWSw34iL2dkBo7AEPK7D_8yMGx3wX3PqqmiNVvv5fNCm6-JPKFl2Puq_TnchVktYCr4Kere-qafCpN_q3jijUl3gWwZ2jMeZMTWp4qmrw6DrXpiDlalmmKhAXZAJYKimZBQ/s1600/transcription.jpg" style="clear: right; margin-bottom: 1em; margin-left: auto; margin-right: auto;"><img border="0" height="124" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhRWjOfFccPlWSw34iL2dkBo7AEPK7D_8yMGx3wX3PqqmiNVvv5fNCm6-JPKFl2Puq_TnchVktYCr4Kere-qafCpN_q3jijUl3gWwZ2jMeZMTWp4qmrw6DrXpiDlalmmKhAXZAJYKimZBQ/s320/transcription.jpg" width="320" /></a></td></tr>
<tr><td class="tr-caption" style="text-align: center;">Image from Paper that Shows Training of DNN for Drug Discovery</td></tr>
</tbody></table>
<div style="text-align: justify;">
The study uses 678 drugs affecting A549, MCF-7 and PC-3 cell lines from <a href="http://www.lincsproject.org/" target="_blank">LINCS</a> library developed by NIH that is linked to 12 therapeutic categories established by MeSH (Medical Subject Heading). The library is maintained by NLM. So basically researchers trained DNN by utilising both transcriptomic data using a scoring algorithm for samples that are perturbed with different concentration of the drug after 6 or 24 hours. The cross-validation of the model showed that DNN achieved 54.6% accuracy in correctly predicting one out of 12 therapeutic categories for each drug. Interestingly, a large number of the drugs that were misclassified by DNN was found to have dual therapeutic utility. This suggests that may be the confusion matrix used for DNN can be used for drug repurposing</div>
<div>
<br /></div>
<div>
This is the first study where DNN based model was developed on the basis of transcriptomic data for predicting the therapeutic use of the drug. Hence, it was proof of concept study that DNNs can be used for annotation of drugs using transcriptomic signatures. Hence, they used this finding to progress towards the development of a pipeline program in order to accelerate the preclinical of drugs for most any therapeutic category. They believe that if this technique can be extrapolated to invite signatures then maybe this can double the number of molecules in drug discovery studies.<span style="text-align: center;"> </span></div>
<div>
<br /></div>
</div>
Rochhttp://www.blogger.com/profile/10226480566630388819noreply@blogger.com11tag:blogger.com,1999:blog-8173239423928249815.post-52196749901118007862016-04-10T05:48:00.003-07:002016-04-10T05:48:57.618-07:00Anti-ageing Molecules Translation to Clinic And Conference <br />
<div class="page" title="Page 2">
<div class="section">
<div class="layoutArea">
<div class="column">
<div style="text-align: justify;">
<span style="font-family: "advpsft";">Aging is a major risk factor for a number of chronic diseases, including
cancer, type II diabetes, atherosclerosis, hypertension, myocardial
infarction, stroke, and neurodegenerative diseases. In animal models,
treatments that extend lifespan often protect against these chronic
diseases and there is a reason to believe that a similar approach might
work in humans. Therefore, the geroscience concept, which aims to
prolong the healthy state of the human body, is likely to become a key
paradigm of biomedicine in developed countries in coming decades
(Seals </span><span style="font-family: "advpsft";">et al.</span><span style="font-family: "advpsft";">, 2015) .</span></div>
<div style="text-align: justify;">
<span style="font-family: "advpsft";"><br /></span></div>
<div style="text-align: justify;">
</div>
<div class="page" title="Page 2">
<div class="section">
<div class="layoutArea">
<div class="column">
<div style="text-align: justify;">
<span style="font-family: "advpsft";">Today, more than 200 substances belong to this
group, each reported to slow aging and/or increase lifespan in a variety
of organisms, including yeasts, nematodes, fruit flies, and rodents,
according to the Geroprotectors.org database. </span><span style="font-family: "advpsft";">Despite such an impressive rate of discovery, not a single geropro-
tector has yet reached the pharmaceutical market as a recognized
intervention targeting aging.</span></div>
<div style="text-align: justify;">
<span style="font-family: "advpsft";"><br /></span></div>
<div style="text-align: justify;">
<span style="font-family: "advpsft";">This is due following reasons</span></div>
<div style="text-align: justify;">
<span style="font-family: "advpsft";"><br /></span></div>
<div style="text-align: justify;">
<span style="font-family: "advpsft";">a) T</span><span style="font-family: "advpsft";">here is
no unified mechanistic concept of aging, and primary triggers of aging
are still poorly understood.</span></div>
<div style="text-align: justify;">
<span style="font-family: "advpsft";"><br /></span></div>
<div style="text-align: justify;">
<span style="font-family: "advpsft";">b) T</span><span style="font-family: "advpsft";">here is no comprehensive system of objective human aging biomarkers.</span></div>
<div style="text-align: justify;">
<span style="font-family: "advpsft";"><br /></span></div>
<div style="text-align: justify;">
<span style="font-family: "advpsft";">c) A</span><span style="font-family: "advpsft";">ging is
not recognized as a disease or a complex of syndromes</span></div>
<div style="text-align: justify;">
<span style="font-family: "advpsft";"><br /></span></div>
<div style="text-align: justify;">
<span style="font-family: "advpsft";">d) T</span><span style="font-family: "advpsft";">he scientific community has no consensus view on the concept of geroprotectors, on
selection criteria for potential geroprotectors, or on the development of
appropriate classification schemes, efficiency ratings, and approaches for
predicting and modeling geroprotective properties.</span></div>
<div style="text-align: justify;">
<span style="font-family: "advpsft";"><br /></span>
<span style="font-family: "advpsft";"><a href="http://www.agingcell.com/2015/11/is-ageing-really-disease.html" target="_blank">This issue has been previously discussed in researchgate and other sites..</a></span><br />
<span style="font-family: "advpsft";"><br /></span>
<span style="font-family: advpsft;">According to GeneAge Database....there are around 1825 genes whose knockdown, knockout or overexpression is known to result in an increase in life span.</span></div>
<div style="text-align: justify;">
<span style="font-family: "advpsft";"><br /></span>
<span style="font-family: "advpsft";">In recent review article published by Dr. </span><span style="font-family: "advpsft";">Alex Zhavoronkov discusses about the primary selection criteria for the geroprotectors.<span style="font-family: "advpsft";"><span style="font-size: 11px;">.........................................................</span><i><a href="https://www.researchgate.net/publication/297760200_Developing_criteria_for_evaluation_of_geroprotectors_as_a_key_stage_toward_translation_to_the_clinic" target="_blank">Click here for downloading the article</a></i></span></span><br />
<span style="font-family: "advpsft";"><span style="font-family: "advpsft";"><i><br /></i></span></span>
<span style="font-family: "advpsft";">Most commonly used geroprotectors</span><br />
<span style="font-family: "advpsft";"><br /></span>
<span style="font-family: "advpsft";">Acarbose</span><br />
<span style="font-family: "advpsft";">Dephernyl</span><br />
<span style="font-family: "advpsft";">D-glucosamine</span><br />
<span style="font-family: "advpsft";">Dihydroergocristine methanesulfonate</span><br />
<span style="font-family: "advpsft";">Ellagic acid</span><br />
<span style="font-family: "advpsft";">Glutathione</span><br />
<span style="font-family: "advpsft";">Metformin</span><br />
<span style="font-family: "advpsft";">Vinpocetine</span><br />
<span style="font-family: "advpsft";"><br /></span>
<span style="font-family: "advpsft";">All these molecules are et</span><br />
<span style="font-family: "advpsft";"><br /></span>
<span style="font-family: "advpsft";">In addition the there is a conference on longevity in Russia............<a href="http://ivaoconf.com/" target="_blank">click here for registration</a></span><br />
<span style="font-family: "advpsft";"><br /></span>
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEheol1xoXxMlo2iZn-Sdfp48RNvfYljNjoKvG6di60vhote1Knf_IDuDoiUuvRreiOLtSkrO5PGnA_scXTT4cKgusJd-e1xvWmTTQNWFTy0cL7KbBjv0Qagk2Ur18t8AvpA2eiWBpUn9Sc/s1600/Screen+Shot+2016-04-09+at+11.46.04+PM.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="140" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEheol1xoXxMlo2iZn-Sdfp48RNvfYljNjoKvG6di60vhote1Knf_IDuDoiUuvRreiOLtSkrO5PGnA_scXTT4cKgusJd-e1xvWmTTQNWFTy0cL7KbBjv0Qagk2Ur18t8AvpA2eiWBpUn9Sc/s400/Screen+Shot+2016-04-09+at+11.46.04+PM.png" width="400" /></a></div>
<div class="separator" style="clear: both; text-align: center;">
<br /></div>
<div class="separator" style="clear: both; text-align: left;">
Recent studies shows that these molecules may be anticancer drugs but may also be useful in attaining longevity. People interested in longevity conference and to learn more about the recent advancement in cancer therapy can visit the above page.</div>
<div class="separator" style="clear: both; text-align: left;">
<br /></div>
<span style="font-family: "advpsft";"><br /></span></div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
Rochhttp://www.blogger.com/profile/10226480566630388819noreply@blogger.com8tag:blogger.com,1999:blog-8173239423928249815.post-14447467249509971122016-02-18T06:13:00.001-08:002016-02-18T06:13:47.442-08:00Insilico Medicine launches Aging.AI -- deep-learned predictor of age trained on blood tests<a href="http://www.eurekalert.org/pub_releases/2016-02/imi-iml021716.php#.VsXRdPN48rB.blogger">Insilico Medicine launches Aging.AI -- deep-learned predictor of age trained on blood tests</a>: Insilico Medicine launched aging.AI, a system allowing users to guess their age and gender by entering the results of their blood test.Unknownnoreply@blogger.com4tag:blogger.com,1999:blog-8173239423928249815.post-2429331199368674072016-02-09T23:03:00.003-08:002016-02-11T06:47:30.993-08:00Anti Ageing Drugs and Molecules<div style="text-align: justify;">
<h2>
Increased Life Expectancy</h2>
Anti-ageing and reversing it seems to be a science fiction. However, technological innovations are being developed to achieve this goal. Longevity is also sited in ancient hindu literature (<a href="http://www.agingcell.com/2015/11/anti-ageing-reality-or-myth.html" target="_blank">click here</a>). Attaining longer life has been a major quest for many eminent researchers and pharmaceutical companies (some of them are listed in table 1).<br />
<br />
<style type="text/css">
table.tableizer-table {
font-size: 12px;
border: 1px solid #CCC; font-family: Times New Roman, Times, serif;
}
.tableizer-table td {
padding: 4px;
margin: 3px;
border: 1px solid #ccc;
}
.tableizer-table th {
background-color: #104E8B;
color: #FFF;
font-weight: bold;
}
</style>
<br />
<table class="tableizer-table">
<tbody>
<tr class="tableizer-firstrow"><th>Scientists</th><th>Primary Institution</th></tr>
<tr><td>Alex Zhavoronkov</td><td><a href="http://insilicomedicine.com/" target="_blank">Insilico Inc.</a></td></tr>
<tr><td>David Sinclair</td><td><a href="http://www.hms.harvard.edu/dms/bbs/fac/sinclair.php" target="_blank">Harvard Medical School</a></td></tr>
<tr><td>Aubrey de Grey</td><td><a href="http://www.sens.org/" target="_blank">SENSE Research Foundation</a></td></tr>
</tbody></table>
<br />
<br />
I have often seen following FAQs on ageing problem in variety of discussion forums:<br />
<br /></div>
<div style="text-align: right;">
</div>
<div style="text-align: justify;">
a) Is it possible to slow down ageing?</div>
<div style="text-align: justify;">
b) Is it possible to live longer than 100 years?</div>
<div style="text-align: justify;">
c) Is reversing of ageing possible?<br />
<br />
<table align="center" cellpadding="0" cellspacing="0" class="tr-caption-container" style="margin-left: auto; margin-right: auto; text-align: center;"><tbody>
<tr><td style="text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgMMAXBxQSx0bAxlTSRtYwQ3F-t02oExlkjxPdMxAV2-sNPWH1-IedcZhiq7hucdBMG4EbzisxAVx2PYrgZysHRkdYjjDCBF3MY-qrsBQRYn457FOeX0P4wINCoeZnYjPzNA-imJGb2ke8/s1600/1.jpg" imageanchor="1" style="margin-left: auto; margin-right: auto;"><img border="0" height="194" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgMMAXBxQSx0bAxlTSRtYwQ3F-t02oExlkjxPdMxAV2-sNPWH1-IedcZhiq7hucdBMG4EbzisxAVx2PYrgZysHRkdYjjDCBF3MY-qrsBQRYn457FOeX0P4wINCoeZnYjPzNA-imJGb2ke8/s320/1.jpg" width="320" /></a></td></tr>
<tr><td class="tr-caption" style="text-align: center;"><b>Figure 1: </b>Top 10 countries with increased life expectancy</td></tr>
</tbody></table>
In light of the above mentioned questions it is certainly possible to slow, reverse and live longer. Evidences of long living <a href="http://www.agingcell.com/2015/11/cancer-resistant-and-long-living-rodent.html" target="_blank">naked mole rats</a>, longest living lady <a href="http://www.agingbiomarkers.com/2015/11/diagnosis-of-ageing.html" target="_blank">Jeanne Louise Calmest</a> and based on the life expectancy data of WHO <b>(figure 1)</b> and "Our World in Data" shows <b>(figure 2)</b> increase in average life expectancy in last 160 years.</div>
<br />
<table align="center" cellpadding="0" cellspacing="0" class="tr-caption-container" style="margin-left: auto; margin-right: auto; text-align: center;"><tbody>
<tr><td style="text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgrnJKorgPmWAcQlqU394miQxCcKttikFtAUwH2dGXEL8_3-QGyRY_9yRX0a85runnSkMl1fglt1ZEUi9BQ5Tv0yMAjcJqMtGgPFY31-swrYBGkYaWpkTF_hYgirqaa1kzW8vB2loAfhpY/s1600/2.jpg" imageanchor="1" style="margin-left: auto; margin-right: auto;"><img border="0" height="159" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgrnJKorgPmWAcQlqU394miQxCcKttikFtAUwH2dGXEL8_3-QGyRY_9yRX0a85runnSkMl1fglt1ZEUi9BQ5Tv0yMAjcJqMtGgPFY31-swrYBGkYaWpkTF_hYgirqaa1kzW8vB2loAfhpY/s320/2.jpg" width="320" /></a></td></tr>
<tr><td class="tr-caption" style="text-align: center;"><b>Figure 2:</b> Increase In Life Expectancy over 160 Years</td></tr>
</tbody></table>
<blockquote class="tr_bq">
<span style="text-align: justify;">These results indicates that there is a chance of increasing life expectancy.</span></blockquote>
<h2>
Molecules For Anti-ageing</h2>
<div style="text-align: justify;">
Ironically, drinking wine can help in anti-ageing. It doesn't mean that people should be drunk to achieve a long life (seems to be impractical). A Harvard Professor,<b> Dr. David Sinclair</b> discovered that the active ingredient of red wine (called as resveratrol)<span style="background-color: white; color: #252525; font-family: sans-serif; font-size: 14px;"> </span>obtained from black grapes may be responsible for anti-ageing by activating SIRT1 de-actylase mediated mechanism at cellular level (<a href="http://science.sciencemag.org/content/sci/339/6124/1216.full.pdf?sid=b369173a-02a4-4f5c-b693-4a1e4e870a4d" target="_blank">Science Magazine</a>). They found that natural (resveratrol) and synthetic sirtuin activating compounds (STACs) may help in anti-ageing by targeting SIRT1. Resveratrol supplements are available by pharmaceutical companies for consumption on <a href="https://www.blogger.com/"><span id="goog_728098464"></span>amazon</a>. Following TEDMED video of Prof. Sinclair explains the importance of anti-ageing research and how to achieve it at cellular level can be seen here.<br />
<br />
<div class="separator" style="clear: both; text-align: center;">
<iframe allowfullscreen="" class="YOUTUBE-iframe-video" data-thumbnail-src="https://i.ytimg.com/vi/DHd5P6sC9IY/0.jpg" frameborder="0" height="266" src="https://www.youtube.com/embed/DHd5P6sC9IY?feature=player_embedded" width="320"></iframe></div>
<br />
<br />
<table cellpadding="0" cellspacing="0" class="tr-caption-container" style="float: right; margin-left: 1em; text-align: right;"><tbody>
<tr><td style="text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjPn1G7hv-dq7zQQl90OUheEbieHgfEh4kXp9EsD2CeeoBPckKoyCVkc-afEQHY7UI8dmBL7NAnApUaSSqadT1hjv8X-Qm9Xe-VkW7GFlyvoXKef0-6OGykXDcD7fcFbhJ2kDkJkWQAoog/s1600/3.jpg" imageanchor="1" style="clear: right; margin-bottom: 1em; margin-left: auto; margin-right: auto;"><img border="0" height="150" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjPn1G7hv-dq7zQQl90OUheEbieHgfEh4kXp9EsD2CeeoBPckKoyCVkc-afEQHY7UI8dmBL7NAnApUaSSqadT1hjv8X-Qm9Xe-VkW7GFlyvoXKef0-6OGykXDcD7fcFbhJ2kDkJkWQAoog/s200/3.jpg" width="200" /></a></td></tr>
<tr><td class="tr-caption" style="text-align: center;"><b>Figure 3:</b> Resveratrol and Wine In Anti-aging</td></tr>
</tbody></table>
</div>
<div style="text-align: justify;">
Although, this discovery is an important scientific finding towards attaining longevity. However, it is difficult to say with certainty, if resveratrol will work effectively in human conditions because of its complexity. </div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Another commonly used molecule for anti-ageing application is Curcumin. Similar to resveratrol this molecule is also available from food material (figure 4) and it forms one the most common ingredient of Indian Spices. Curcumin is a phytochemical molecule and it may help slowing ageing process by inhibiting mTOR pathway.</div>
<table cellpadding="0" cellspacing="0" class="tr-caption-container" style="float: left; margin-right: 1em; text-align: left;"><tbody>
<tr><td style="text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgdzEedEaVURVlJiP5D0pBcFZoe6VHIP2ghkzwdgL3GpnoB436mbCRbuXw459BmEBHY07pnLCAGybUdbpwt1eGyc0-9_gKVSqDMqIwW6gS4Qg1R9b1WHAlKXppaVpzAV0DLqmJGHj-pmz0/s1600/4.jpg" imageanchor="1" style="clear: left; margin-bottom: 1em; margin-left: auto; margin-right: auto;"><img border="0" height="152" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgdzEedEaVURVlJiP5D0pBcFZoe6VHIP2ghkzwdgL3GpnoB436mbCRbuXw459BmEBHY07pnLCAGybUdbpwt1eGyc0-9_gKVSqDMqIwW6gS4Qg1R9b1WHAlKXppaVpzAV0DLqmJGHj-pmz0/s200/4.jpg" width="200" /></a></td></tr>
<tr><td class="tr-caption" style="text-align: center;"><b>Figure 4:</b> Curcumin</td></tr>
</tbody></table>
<br />
<div style="text-align: justify;">
Molecules like resveratrol and curcumin have shown to be the proof of principle that there is a possibility of attaining long life by slowing the ageing process. Eminent researchers are still struggling to find newer and better molecule which may help in anti-ageing by targeting telomeres, m-TOR or SIRT1. Further, following documented video by <b>Dr. Alex Zhavoronkov</b> showcase Insilco Inc. finding about healthy ageing in an international symposium as shown below:</div>
<div style="text-align: justify;">
<br /></div>
<div class="separator" style="clear: both; text-align: center;">
<iframe allowfullscreen="" class="YOUTUBE-iframe-video" data-thumbnail-src="https://i.ytimg.com/vi/ot609QCT5Jk/0.jpg" frameborder="0" height="266" src="https://www.youtube.com/embed/ot609QCT5Jk?feature=player_embedded" width="320"></iframe></div>
<div style="text-align: justify;">
<br /></div>
<br />
Insilco Inc under leadership of Dr. Alex is not only trying to study ageing at molecular level but also trying to fight against age related disease by developing personalised medicine segment. In addition to the use of these molecular findings a new mobile app is developed by <a href="https://play.google.com/store/apps/details?id=com.rynkl" target="_blank">RYNLK</a> to detect the effects of these anti-aging molecule by taking selfies. App can be downloaded from the following <a href="https://play.google.com/store/apps/details?id=com.rynkl" target="_blank">link</a>. More technical details about the use of this app can also be <a href="http://www.agingbiomarkers.com/2016/02/mobile-app-to-map-ageing.html" target="_blank">available from here</a><br />
<div class="separator" style="clear: both; text-align: center;">
<br /></div>
Rochhttp://www.blogger.com/profile/10226480566630388819noreply@blogger.com2tag:blogger.com,1999:blog-8173239423928249815.post-55546385262711672962016-01-08T07:45:00.001-08:002016-01-08T07:45:18.599-08:00Beauty Contest And Opportunity For Computational ExpertsUse of artificial intelligence (AI) had been increasing tremendously. Use of AI in air planes and other automobiles are most commonly used and being evolved continuously. But it is interesting even to think that an AI would judge the beauty context.<br />
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgCzf8qFlYiR72VYIq1qbK0ASKza3zWYfLFH4aq8BHKMxZqpHwOK45qphWID1kb9EgoPNSxX3-JSzN1LLdFTkSXzUj4k3RD__T1_pK9C8lWAMLqleTnIYa_00kfKUUW4AfqtpcCngfd85k/s1600/1.jpg" imageanchor="1" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"><img border="0" height="172" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgCzf8qFlYiR72VYIq1qbK0ASKza3zWYfLFH4aq8BHKMxZqpHwOK45qphWID1kb9EgoPNSxX3-JSzN1LLdFTkSXzUj4k3RD__T1_pK9C8lWAMLqleTnIYa_00kfKUUW4AfqtpcCngfd85k/s200/1.jpg" width="200" /></a><br />
<blockquote class="tr_bq">
Parameters for Judging AI beauty Contest?</blockquote>
<br />
<ul>
<li>Wrinkles</li>
<li>Face symmetry</li>
<li>Skin colour</li>
<li>Gender</li>
<li>Age group</li>
<li>Ethnicity and others</li>
</ul>
<div>
Unlike other beauty contests this one is backed by scientists who are working to fight against ageing. It is a normal psychology that people don't worry about how to fight ageing. However, they worry about how they look. It is noted that more than 1 million people take selfies and post them on social networking site. Idea is what if this selfie can be used for winning a first international AI beauty contest.</div>
<div>
<br /></div>
<div>
People who are interested to provide their entries mark deadlines are, Human entries: 15 Jan where as for codes for AI robots: 20 Jan --------------------------Log on this website for <a href="http://beauty.ai/" target="_blank">registration</a></div>
<div>
<br /></div>
<div>
Recently article published in <a href="http://techcrunch.com/2016/01/01/the-first-international-beauty-contest-judged-by-robots/" target="_blank">TechCrunch</a>, organisers/ scientists discussed about their long term plans with their idea to host this beauty contest. </div>
<blockquote class="tr_bq" style="text-align: center;">
<i><b><a href="http://beauty.ai/" target="_blank">Take your selfie and upload your entry today</a> <a href="http://beauty.ai/" target="_blank">through special app available here</a></b></i></blockquote>
Simple rules: No make up<br />
No beard<br />
No glasses<br />
<br />
Understanding of faces through this contest will reveal about the youth and age related aspects. The topic is extensively discussed at <a href="http://techcrunch.com/2016/01/01/the-first-international-beauty-contest-judged-by-robots/" target="_blank">TechCrunch</a>. This is not only an opportunity for people to test their beauty features but also for computational chemists to upload their algorithms for AI which can help in judging human attractiveness.<br />
<br />
<blockquote class="tr_bq" style="text-align: center;">
<i><a href="http://beauty.ai/img/Beauty.AI.pdf" target="_blank">Check the details of uploading your AI entries here.... Hurry!!!</a></i></blockquote>
<br />
<blockquote class="tr_bq">
<br /></blockquote>
Rochhttp://www.blogger.com/profile/10226480566630388819noreply@blogger.com4tag:blogger.com,1999:blog-8173239423928249815.post-68233591999898645102015-11-28T00:43:00.002-08:002015-11-28T00:49:48.962-08:00Ageing-Disease Conundrum<div style="text-align: left;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiTame0Coclte621fMxXkxzxNLz0rL8f_JBzquDPJU2fzhUWm4S2OB739fhm888Aj7f9DRlXaKHeTnp4onPwcZ7E1_w2TWu9wAjW8gt4y4mDcmifITeeCAx-__1t60CtTAL11i-kbyjo7E/s1600/ageing.jpg" imageanchor="1" style="clear: left; float: left; margin-bottom: 1em; margin-right: 1em;"><img border="0" height="133" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiTame0Coclte621fMxXkxzxNLz0rL8f_JBzquDPJU2fzhUWm4S2OB739fhm888Aj7f9DRlXaKHeTnp4onPwcZ7E1_w2TWu9wAjW8gt4y4mDcmifITeeCAx-__1t60CtTAL11i-kbyjo7E/s200/ageing.jpg" width="200" /></a>In line of recent blog post of whether <a href="http://www.agingcell.com/2015/11/is-ageing-really-disease.html" target="_blank">ageing is a disease or not</a>? A news report published in "<a href="https://www.newscientist.com/article/dn28531-label-ageing-as-a-disease-and-unleash-the-hunt-for-a-cure/" target="_blank">New Scientist</a>" brings out an important angle or reason is to why there is a need of including ageing as disease in upcoming International List of Causes of Death <span style="background-color: white; color: #333333; font-family: "pt serif"; font-size: 15px;"> (ICD)-11 </span>classification. Homeostasis is one of the most favourite phenomena of nature. Hence, every idea has its own merits and demerits. </div>
<div style="text-align: left;">
<br /></div>
<div style="text-align: left;">
Upon asking an important question on a scientific forum wether ageing is a disease or not. I was given following reply by a distinguished Professor:</div>
<div style="text-align: left;">
<br /></div>
<blockquote class="tr_bq">
<ol>
<li style="text-align: left;"><strong>yes</strong> ("disorder of structure or function in an animal or plant of such a degree as to produce or threaten to produce detectable illness or disorder").</li>
<li id="yui_3_14_1_1_1448698105978_1968" style="text-align: left;"><strong>no</strong> ("the quality which identifies disease is some deviation from a biological norm").</li>
</ol>
<i></i><br />
<div style="text-align: left;">
<i><i>Is ageing a disease? - ResearchGate</i>. Available from: <a href="https://www.researchgate.net/post/Is_ageing_a_disease">https://www.researchgate.net/post/Is_ageing_a_disease</a> [accessed Nov 28, 2015].</i></div>
<i>
</i></blockquote>
<div style="text-align: left;">
<br /></div>
<div style="text-align: left;">
I can see some clear confusion here. When we see definition "2" as mentioned above; ageing leads to Cardio vascular abnormalities, Central Nervous System (CNS) abnormalities, anatomical abnormalities, fatigue, prostate problems in males and many other problems. Hence, the question Is it not deviation from biological norm?</div>
<div style="text-align: left;">
<br /></div>
<blockquote class="tr_bq" style="text-align: left;">
Moreover, one of the most important question "How much can human life span be extended"? is one of the top <b>25 questions</b> <b>to be answered,</b> published by <i><a href="http://www.sciencemag.org/site/feature/misc/webfeat/125th/" target="_blank">Science magazine</a>.</i></blockquote>
<div style="text-align: left;">
<br /></div>
<div class="separator" style="clear: both; text-align: center;">
</div>
<div style="text-align: left;">
Not including ageing as a disease has created many restriction towards availability of collaborative efforts, funding and other resources for carrying out cutting edge research to solve the problems pertaining to ageing. The question of including ageing as disease has been more of an ethical instead of scientific conundrums as pointed by Dr. Alex Zhavoronkov in his recent press release <a href="https://www.newscientist.com/article/dn28531-label-ageing-as-a-disease-and-unleash-the-hunt-for-a-cure/" target="_blank"><i>here</i></a>. </div>
Rochhttp://www.blogger.com/profile/10226480566630388819noreply@blogger.com5tag:blogger.com,1999:blog-8173239423928249815.post-69554236754081553972015-11-20T07:23:00.001-08:002015-11-20T07:24:16.148-08:00Beauty Contest Judged By Artificial Intelligence.... After looking at the various facets of ageing and its implications on human life. Here, I bring to you an incredible announcement made by leaders in the field finding newer ways of diagnosis and fighting ageing.<br />
<br />
<br />
<blockquote class="tr_bq">
"<a href="http://www.prweb.com/releases/2015/11/prweb13088208.htm" target="_blank">First International Beauty Context Judged by Artificial Intelligence Jury</a>"</blockquote>
<div class="separator" style="clear: both; text-align: center;">
<br /></div>
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiNRLrtbpCSJI_BmxPPTgfZZfDuXljnxtZccArWEvH7d78FzArW3TdmY6_GBckejs39jjOA6YImhg4NRf2DGm4klrcvyBTolSZj6Czz3L5iepBnZeQUcOnMsp_8T_DP7tM2htf4Lf8Ax60/s1600/Screen+Shot+2015-11-21+at+12.13.52+AM.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="103" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiNRLrtbpCSJI_BmxPPTgfZZfDuXljnxtZccArWEvH7d78FzArW3TdmY6_GBckejs39jjOA6YImhg4NRf2DGm4klrcvyBTolSZj6Czz3L5iepBnZeQUcOnMsp_8T_DP7tM2htf4Lf8Ax60/s320/Screen+Shot+2015-11-21+at+12.13.52+AM.png" width="320" /></a></div>
<div class="separator" style="clear: both; text-align: center;">
<br /></div>
<div class="separator" style="clear: both; text-align: center;">
This contest is partnered by big names like Nvidia and Microsoft. You can get more details about rules and regulations on the following <a href="http://www.prweb.com/releases/2015/11/prweb13088208.htm" target="_blank">site</a>.</div>
<div class="separator" style="clear: both; text-align: center;">
<br /></div>
<div class="separator" style="clear: both; text-align: left;">
So go and upload your photo and get the newly developed AI decide if you are beauty queen or king. You can register online and be a part of this unique contest <a href="http://beauty.ai/" target="_blank"><i>here</i></a>.</div>
Rochhttp://www.blogger.com/profile/10226480566630388819noreply@blogger.com6tag:blogger.com,1999:blog-8173239423928249815.post-87420512689990694152015-11-12T07:17:00.000-08:002015-11-12T07:17:16.862-08:00Is ageing really a disease?From my previous discussions on <br />
<br />
A) <a href="http://www.oncologybiomarkers.com/2015/10/personalised-cancer-treatment-by.html" target="_blank">Personalised cancer therapy</a><br />
<br />
B) <a href="http://www.agingcell.com/2015/10/ageing-cancer-dependency.html" target="_blank">Cancer and ageing relation</a><br />
<br />
C) <a href="http://www.agingcell.com/2015/10/important-breakthroughs-in-cancer-and.html" target="_blank">Important breakthroughs in cancer and ageing</a><br />
<br />
D) <a href="http://www.agingcell.com/2015/11/cancer-resistant-and-long-living-rodent.html" target="_blank">Long living rats</a><br />
<br />
E) <a href="http://www.agingcell.com/2015/11/anti-ageing-reality-or-myth.html" target="_blank">Scientific perception of Indian scripture for longevity</a>: Dr. Sinclair and Dr. Zhavoronkov's idea.<br />
<br />
<b><i>It is surprising that ageing is not been classified as a disease.</i></b><br />
<br />
<div style="text-align: justify;">
It is indeed debatable that whether ageing is a disease or a generalised and universally accepted phenomenon? Being a pharmacist or medical practitioners we normally follow guidelines of standards set by World health organisation (WHO), Centre for disease control (CDC), United states pharmacopeia (USP), British pharmacopeia (BP), Indian pharmacopeia (IP) and others. </div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Recently, a paper published by Dr. Alex Zhavoronkov raises a cascade of questions as discussed below.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
If "Ageing" is never been considered as a disease up till now then why are we trying to cure it? or slowing down the process? or trying to find out a molecule which can provide longevity? Why the health supplement industry is growing enormously compared to any other pharmaceutical industry?</div>
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjpglYVaBg_rdapXlt6IzbqEfSbXSgACGDVLys-PrZJnG3y4dim9JpbsNAM6bRa3tTP9aRgsrEpE4Q_m_h4ZZyoc7wvawlWBjPYuOY9S340TkSYKtB9fscGUXoaGNnyt5lKaUcdu-bKkvk/s1600/Screen+Shot+2015-11-12+at+12.51.01+PM.png" imageanchor="1" style="clear: left; float: left; margin-bottom: 1em; margin-right: 1em;"><img border="0" height="320" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjpglYVaBg_rdapXlt6IzbqEfSbXSgACGDVLys-PrZJnG3y4dim9JpbsNAM6bRa3tTP9aRgsrEpE4Q_m_h4ZZyoc7wvawlWBjPYuOY9S340TkSYKtB9fscGUXoaGNnyt5lKaUcdu-bKkvk/s320/Screen+Shot+2015-11-12+at+12.51.01+PM.png" width="211" /></a></div>
<div style="text-align: justify;">
It is evident that cross over from ageing to pathological conditions like age related diseases often takes place as shown in figure. As a result we have deadly diseases like cancer, cardiovascular diseases, central nervous system diseases and others. The paper clearly explains how the united efforts to fight against ageing is most important from both scientific and economic perspective. Importantly, the paper discusses about the reasons why it is essential to classify ageing as disease in up coming 11th international statistical classification of diseases and related health problems (ICD-11), expected to be finalised in 2018.</div>
<br />
<div style="text-align: justify;">
Significance of this paper and insight of Dr. Zhavoronkov, CEO Insilco Inc. is discussed by www.eurekaalert.org. Please click <a href="http://www.eurekalert.org/pub_releases/2015-11/imi-iaa110715.php" target="_blank"><i>here</i></a> for more details.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: right;">
-Paper can be downloaded from <i><a href="https://drive.google.com/open?id=0B5HQq5g8ZsuXblZ3WjhweW1kUmc" target="_blank">here</a></i>.</div>
Rochhttp://www.blogger.com/profile/10226480566630388819noreply@blogger.com28tag:blogger.com,1999:blog-8173239423928249815.post-72448020800198727572015-11-06T19:05:00.000-08:002015-11-06T19:05:01.361-08:00Anti-ageing: A reality or myth?<h3>
From Mahabharata to Science</h3>
<div>
The idea of Not Ageing is indeed like looking into an indian mythology of Mahabharata. </div>
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjYcRTlW6VeNWpqGBvxXm05qn1FAacewSLlp39DQA8MdzRyolGabim9vDBTCbAPsSRpP6aciDW_mdkar6bC_9bE8BtPpMKkdIgHVxirZmy3dt-uiDFspAzH_zTx2aeLCmihhLqsBe1u08Q/s1600/mahabharat.jpg" imageanchor="1" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"><img border="0" height="150" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjYcRTlW6VeNWpqGBvxXm05qn1FAacewSLlp39DQA8MdzRyolGabim9vDBTCbAPsSRpP6aciDW_mdkar6bC_9bE8BtPpMKkdIgHVxirZmy3dt-uiDFspAzH_zTx2aeLCmihhLqsBe1u08Q/s200/mahabharat.jpg" width="200" /></a></div>
<div>
Where people are mentioned to have unusually long lives. It is one of the oldest known Indian scripture researched by many archeologists, medicine experts and physicist. Many known scientists have known to acknowledge this intriguing scripture for their well known scientific works that includes <b>Albert Einstein or J. Robert Oppenheimer. </b></div>
<table cellpadding="0" cellspacing="0" class="tr-caption-container" style="float: left; margin-right: 1em; text-align: left;"><tbody>
<tr><td style="text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEi4Y_gqqyn2msgT1PnorNKmxNqNSzIRUv76Jp_eq-S96zMqAorOa0Q_RMKicSLBCo70WG2J2orbKUyrM3a9i0gmthDh2D43djlFSniu6rHEgmltT0WAEal6_dHyxV96TCTulDCafsCLqMA/s1600/vyasa.jpg" imageanchor="1" style="clear: left; margin-bottom: 1em; margin-left: auto; margin-right: auto;"><img border="0" height="200" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEi4Y_gqqyn2msgT1PnorNKmxNqNSzIRUv76Jp_eq-S96zMqAorOa0Q_RMKicSLBCo70WG2J2orbKUyrM3a9i0gmthDh2D43djlFSniu6rHEgmltT0WAEal6_dHyxV96TCTulDCafsCLqMA/s200/vyasa.jpg" width="155" /></a></td></tr>
<tr><td class="tr-caption" style="text-align: center;">Depicted Image of Sage Vyasa</td></tr>
</tbody></table>
<div>
<br /></div>
<div>
It is said that people had long lives in ancient era of Mahabharata that is around 1000 years. May be this is a truth or myth. Sage Vyasa who is known to have written this ancient scripture lived across approximately 6 generation of kings and have narrated their stories in Mahabharata. Some people with their logical reasoning think that he may have lived around 130 years without any health issues. Whereas, some assume that he may have lived way longer than that.</div>
<table cellpadding="0" cellspacing="0" class="tr-caption-container" style="float: right; margin-left: 1em; text-align: right;"><tbody>
<tr><td style="text-align: center;"> <a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgKbxBYQy5eEHhXwYlVvjAr9jAV9ewnewxLtsdyFKCDofW2k0L8MiSJx1HEYHUh1dMK2Yz0yVUz-DlbI1EYWiRuyT4KxYXu8LzSCX2t4R9mN7cxPpX7WvLToCuxedm3UHIErt_X-xjxzU8/s1600/bhishma.jpg" imageanchor="1" style="clear: right; margin-bottom: 1em; margin-left: auto; margin-right: auto;"><img border="0" height="150" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgKbxBYQy5eEHhXwYlVvjAr9jAV9ewnewxLtsdyFKCDofW2k0L8MiSJx1HEYHUh1dMK2Yz0yVUz-DlbI1EYWiRuyT4KxYXu8LzSCX2t4R9mN7cxPpX7WvLToCuxedm3UHIErt_X-xjxzU8/s200/bhishma.jpg" width="200" /></a></td></tr>
<tr><td class="tr-caption" style="text-align: center;"> Lord Krishna and Bhisma (symbol of longevity)</td></tr>
</tbody></table>
<div>
<b><i><br /></i></b></div>
<div>
<b><i><br /></i></b></div>
<div>
<b><i><br /></i></b></div>
<div>
<b><i><br /></i></b></div>
<div>
<b><i>Important point is that we have reference of longevity in ancient literature, question is do we believe in having scientific basis for long and healthy life?</i></b></div>
<div>
<h4>
Voice of Insilco Inc, CEO: Dr. Alex Zhavoronkov<iframe allowfullscreen="" class="YOUTUBE-iframe-video" data-thumbnail-src="https://i.ytimg.com/vi/pGdRDJ-MLtc/0.jpg" frameborder="0" height="266" src="https://www.youtube.com/embed/pGdRDJ-MLtc?feature=player_embedded" width="320"></iframe></h4>
It shows a far fetched vision of company which truly believes that longevity is possible. But is it a dream/ struggle or some kind of myth? <span style="text-align: justify;">Evidence of </span><a href="http://www.agingcell.com/2015/11/cancer-resistant-and-long-living-rodent.html" style="text-align: justify;" target="_blank">naked mole rat</a><span style="text-align: justify;"> discussed previously in our blogs suggests that this may be possible. As it is the only rodent, which points in the direction of not only having resistance towards cancer but also towards other age related diseases. </span><br />
<br />
<span style="text-align: justify;">A group of scientists believe that at cellular levels, </span><a href="http://www.agingcell.com/2015/10/important-breakthroughs-in-cancer-and.html" style="text-align: justify;" target="_blank">mTOR and Telomerase</a><span style="text-align: justify;"> may play a crucial role in cancer therapy and attaining longevity as discussed previously. </span><span style="text-align: justify;">On the other hand </span><a href="https://en.wikipedia.org/wiki/David_Sinclair_%28biologist%29" style="text-align: justify;" target="_blank">Prof. David Sinclair</a><span style="text-align: justify;"> in his video published in TEDx series explains his life's journey to find reason behind ageing.</span></div>
<h1 class="yt watch-title-container" style="border: 0px; color: #222222; display: table-cell; font-family: Roboto, arial, sans-serif; font-size: 24px; font-weight: normal; line-height: normal; margin: 0px 0px 13px; padding: 0px; vertical-align: top; width: 610px; word-wrap: break-word;">
<br /></h1>
<div class="separator" style="clear: both; text-align: left;">
<iframe width="320" height="266" class="YOUTUBE-iframe-video" data-thumbnail-src="https://i.ytimg.com/vi/vCCdmGKtxPA/0.jpg" src="https://www.youtube.com/embed/vCCdmGKtxPA?feature=player_embedded" frameborder="0" allowfullscreen></iframe></div>
<br />
He talks about one more miraculous protein which may be involved in ageing process called as Sirtuin. .............................................. yeast ageing mechanism <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Accelerated+aging+and+nucleolar+fragmentation+in+yeast+sgs1+mutants" target="_blank"><i>click here</i></a>.<br />
............................................... role of sirtuin in age related diseases <a href="http://www.ncbi.nlm.nih.gov/pubmed/26521204" target="_blank"><i>click here</i></a>.<br />
<br />
Perhaps, this insight may help in unrevealing deeper mysteries of long life and a way to treat cancer by using <a href="http://www.oncologybiomarkers.com/2015/10/personalised-cancer-treatment-by.html" target="_blank">Personalised medicine method</a>.Rochhttp://www.blogger.com/profile/10226480566630388819noreply@blogger.com3tag:blogger.com,1999:blog-8173239423928249815.post-62953434826777290662015-11-03T03:32:00.000-08:002015-11-04T03:39:16.057-08:00Cancer Resistant And long Living RodentIn our previous blogs we discussed about <a href="http://www.agingcell.com/2015/10/important-breakthroughs-in-cancer-and.html">Peto's paradox.</a> We also discussed about <a href="http://www.oncologybiomarkers.com/2015/10/personalised-cancer-treatment-by.html" target="_blank">personalised medicine</a> for cancer therapy and <a href="http://www.oncologybiomarkers.com/2015/10/cancer-research-funding-and-major.html" target="_blank">funding possibilities </a>for fighting against cancer.<br />
<br />
In most published literature mice are often used as model to extrapolate molecular research for cancer and ageing to human conditions. This extrapolation often fails due to variation in molecular and metabolic levels. For more details please check <i><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1369270/" target="_blank">here</a></i>.<br />
<a href="https://www.blogger.com/blogger.g?blogID=8173239423928249815" imageanchor="1" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"></a><a href="webkit-fake-url://9ba2415b-873d-45b7-b658-36831b6bac60/image.tiff" imageanchor="1" style="clear: left; float: left; margin-bottom: 1em; margin-right: 1em;"></a><br />
Further, we also discussed recent strategies of using targets like <a href="http://www.agingcell.com/2015/10/important-breakthroughs-in-cancer-and.html" target="_blank">mTOR and Telomerase </a>for treating cancer and age related diseases.<br />
<h2 style="text-align: left;">
<i><span style="font-size: small;">Important question is mice (a rodent species) be used for getting useful information about problems of fighting cancer or longevity?</span></i></h2>
<div class="separator" style="clear: both; text-align: left;">
<iframe width="320" height="266" class="YOUTUBE-iframe-video" data-thumbnail-src="https://i.ytimg.com/vi/rxCXyVtN-_E/0.jpg" src="https://www.youtube.com/embed/rxCXyVtN-_E?feature=player_embedded" frameborder="0" allowfullscreen></iframe></div>
<div class="separator" style="clear: both; text-align: left;">
<span style="text-align: center;">video of showing of naked mole rats can help preventing cancer</span></div>
<div>
<br /></div>
<div style="text-align: left;">
It is said that "Answer to major natural problems will come nature". Somewhere in 2013 it was discovered that a species of mice, which shows resistance to cancer it is called as "Mole Rats"</div>
<div style="text-align: left;">
<br /></div>
<div style="line-height: normal;">
<div class="separator" style="clear: both; text-align: left;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiQugTh93lda5KeiRIGOV7dP8DWHqTYS8F_pZs_Tg3oOfKBtVvnWTW0t10t9wp0gShSzddsIZHRueJGknTIUkE0-Rf4JviC-tBWMS5o30mDMYi5pNzGTQWXWePxusLZKFRBVHl4KDxzseE/s1600/1.jpg" imageanchor="1" style="clear: left; float: left; margin-bottom: 1em; margin-right: 1em;"><img border="0" height="220" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiQugTh93lda5KeiRIGOV7dP8DWHqTYS8F_pZs_Tg3oOfKBtVvnWTW0t10t9wp0gShSzddsIZHRueJGknTIUkE0-Rf4JviC-tBWMS5o30mDMYi5pNzGTQWXWePxusLZKFRBVHl4KDxzseE/s320/1.jpg" width="320" /></a></div>
Although, it is a ugly looking <b>nude mice but it is an interesting animal showing resistance to cancer. </b></div>
<div style="line-height: normal;">
<br />
For more details about the animal please read <i><a href="http://www.nature.com/news/simple-molecule-prevents-mole-rats-from-getting-cancer-1.13236" target="_blank">here</a></i>.</div>
<div style="line-height: normal;">
<br />
A simple molecule called hyaluronic acid (HA) produced by this animal is responsible for preventing development of cancer. However, scientists believed that there may be more to this idea. They think that other mechanisms along HA induced effects may play role in preventing developing cancer in mole rats. </div>
<div style="line-height: normal;">
<br /></div>
<div style="line-height: normal;">
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEg0RpJYYLBwRjVXIU6T6MgXjm_A9itbUg4LKkNrjgtJzhyUyRdsbsnqYnbrZuyhq_2-fCwXcLCTK6Rv6ugH2rdcXbDEWVz2Jnxz_0cImEDMwVcLDpS58yssSwgbJ-8gRzqegVHrxGCPWns/s1600/Screen+Shot+2015-11-03+at+12.08.44+AM.png" imageanchor="1" style="clear: left; float: left; margin-bottom: 1em; margin-right: 1em;"><img border="0" height="70" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEg0RpJYYLBwRjVXIU6T6MgXjm_A9itbUg4LKkNrjgtJzhyUyRdsbsnqYnbrZuyhq_2-fCwXcLCTK6Rv6ugH2rdcXbDEWVz2Jnxz_0cImEDMwVcLDpS58yssSwgbJ-8gRzqegVHrxGCPWns/s320/Screen+Shot+2015-11-03+at+12.08.44+AM.png" width="320" /></a></div>
Unusually, molecular weight of HA from mole rat is five times higher than humans which provides protection to mole rats against cancer. Scientific paper can be accessed <i><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3720720/" target="_blank">here</a></i>.</div>
<div style="line-height: normal;">
<br /></div>
<div style="line-height: normal;">
Please click <a href="http://www.naked-mole-rat.org/" target="_blank"><i>here</i></a> to check genome sequence web-portal for more in-depth research.</div>
<div style="line-height: normal;">
<br /></div>
<div style="line-height: normal;">
This rat seems to be resistant to age related diseases including cancer. Further, it has striking life of 30 years, that is longer than the normal mouse with life span of maximum 4 years. This makes mole rats an unusually long living rodents. More details can be seen <i><a href="http://www.nature.com/nature/journal/vaop/ncurrent/abs/nature12234.html" target="_blank">here</a></i>.<br />
<br />
Hence, unfolding of the biomechanics of this organism may help us to find newer ways of cancer therapy and attaining longer life.<br />
<br />
Some sources says "If a human was to have same lifespan as a naked mole rat, relative to its size, they would live for up to 600 years"............................<a href="http://www.dailymail.co.uk/sciencetech/article-2940867/Could-naked-mole-rats-help-stop-cancer-Rodents-produce-hybrid-protein-stops-tumour-growth.html" target="_blank"><i>click here</i></a>.<span style="background-color: white;"><span style="font-family: inherit;"></span></span><br />
<span style="background-color: white;">
<!--[if gte mso 9]><xml>
<o:DocumentProperties>
<o:Revision>0</o:Revision>
<o:TotalTime>0</o:TotalTime>
<o:Pages>1</o:Pages>
<o:Words>49</o:Words>
<o:Characters>282</o:Characters>
<o:Company>BioNano </o:Company>
<o:Lines>2</o:Lines>
<o:Paragraphs>1</o:Paragraphs>
<o:CharactersWithSpaces>330</o:CharactersWithSpaces>
<o:Version>14.0</o:Version>
</o:DocumentProperties>
<o:OfficeDocumentSettings>
<o:AllowPNG/>
</o:OfficeDocumentSettings>
</xml><![endif]-->
<!--[if gte mso 9]><xml>
<w:WordDocument>
<w:View>Normal</w:View>
<w:Zoom>0</w:Zoom>
<w:TrackMoves/>
<w:TrackFormatting/>
<w:PunctuationKerning/>
<w:ValidateAgainstSchemas/>
<w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
<w:IgnoreMixedContent>false</w:IgnoreMixedContent>
<w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
<w:DoNotPromoteQF/>
<w:LidThemeOther>EN-US</w:LidThemeOther>
<w:LidThemeAsian>JA</w:LidThemeAsian>
<w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>
<w:Compatibility>
<w:BreakWrappedTables/>
<w:SnapToGridInCell/>
<w:WrapTextWithPunct/>
<w:UseAsianBreakRules/>
<w:DontGrowAutofit/>
<w:SplitPgBreakAndParaMark/>
<w:EnableOpenTypeKerning/>
<w:DontFlipMirrorIndents/>
<w:OverrideTableStyleHps/>
<w:UseFELayout/>
</w:Compatibility>
<m:mathPr>
<m:mathFont m:val="Cambria Math"/>
<m:brkBin m:val="before"/>
<m:brkBinSub m:val="--"/>
<m:smallFrac m:val="off"/>
<m:dispDef/>
<m:lMargin m:val="0"/>
<m:rMargin m:val="0"/>
<m:defJc m:val="centerGroup"/>
<m:wrapIndent m:val="1440"/>
<m:intLim m:val="subSup"/>
<m:naryLim m:val="undOvr"/>
</m:mathPr></w:WordDocument>
</xml><![endif]--><!--[if gte mso 9]><xml>
<w:LatentStyles DefLockedState="false" DefUnhideWhenUsed="true"
DefSemiHidden="true" DefQFormat="false" DefPriority="99"
LatentStyleCount="276">
<w:LsdException Locked="false" Priority="0" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Normal"/>
<w:LsdException Locked="false" Priority="9" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="heading 1"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 2"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 3"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 4"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 5"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 6"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 7"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 8"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 9"/>
<w:LsdException Locked="false" Priority="39" Name="toc 1"/>
<w:LsdException Locked="false" Priority="39" Name="toc 2"/>
<w:LsdException Locked="false" Priority="39" Name="toc 3"/>
<w:LsdException Locked="false" Priority="39" Name="toc 4"/>
<w:LsdException Locked="false" Priority="39" Name="toc 5"/>
<w:LsdException Locked="false" Priority="39" Name="toc 6"/>
<w:LsdException Locked="false" Priority="39" Name="toc 7"/>
<w:LsdException Locked="false" Priority="39" Name="toc 8"/>
<w:LsdException Locked="false" Priority="39" Name="toc 9"/>
<w:LsdException Locked="false" Priority="35" QFormat="true" Name="caption"/>
<w:LsdException Locked="false" Priority="10" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Title"/>
<w:LsdException Locked="false" Priority="1" Name="Default Paragraph Font"/>
<w:LsdException Locked="false" Priority="11" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Subtitle"/>
<w:LsdException Locked="false" Priority="22" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Strong"/>
<w:LsdException Locked="false" Priority="20" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Emphasis"/>
<w:LsdException Locked="false" Priority="59" SemiHidden="false"
UnhideWhenUsed="false" Name="Table Grid"/>
<w:LsdException Locked="false" UnhideWhenUsed="false" Name="Placeholder Text"/>
<w:LsdException Locked="false" Priority="1" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="No Spacing"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 1"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 1"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 1"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 1"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 1"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 1"/>
<w:LsdException Locked="false" UnhideWhenUsed="false" Name="Revision"/>
<w:LsdException Locked="false" Priority="34" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="List Paragraph"/>
<w:LsdException Locked="false" Priority="29" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Quote"/>
<w:LsdException Locked="false" Priority="30" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Intense Quote"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 1"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 1"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 1"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 1"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 1"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 1"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 1"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 1"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 2"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 2"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 2"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 2"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 2"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 2"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 2"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 2"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 2"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 2"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 2"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 2"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 2"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 2"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 3"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 3"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 3"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 3"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 3"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 3"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 3"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 3"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 3"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 3"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 3"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 3"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 3"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 3"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 4"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 4"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 4"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 4"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 4"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 4"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 4"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 4"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 4"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 4"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 4"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 4"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 4"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 4"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 5"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 5"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 5"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 5"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 5"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 5"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 5"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 5"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 5"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 5"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 5"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 5"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 5"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 5"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 6"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 6"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 6"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 6"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 6"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 6"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 6"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 6"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 6"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 6"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 6"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 6"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 6"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 6"/>
<w:LsdException Locked="false" Priority="19" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Subtle Emphasis"/>
<w:LsdException Locked="false" Priority="21" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Intense Emphasis"/>
<w:LsdException Locked="false" Priority="31" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Subtle Reference"/>
<w:LsdException Locked="false" Priority="32" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Intense Reference"/>
<w:LsdException Locked="false" Priority="33" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Book Title"/>
<w:LsdException Locked="false" Priority="37" Name="Bibliography"/>
<w:LsdException Locked="false" Priority="39" QFormat="true" Name="TOC Heading"/>
</w:LatentStyles>
</xml><![endif]-->
<!--[if gte mso 10]>
<style>
/* Style Definitions */
table.MsoNormalTable
{mso-style-name:"Table Normal";
mso-tstyle-rowband-size:0;
mso-tstyle-colband-size:0;
mso-style-noshow:yes;
mso-style-priority:99;
mso-style-parent:"";
mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
mso-para-margin:0cm;
mso-para-margin-bottom:.0001pt;
mso-pagination:widow-orphan;
font-size:12.0pt;
font-family:"Times New Roman";}
</style>
<![endif]-->
<!--StartFragment-->
<!--EndFragment--></span><br />
<div class="MsoNormal">
<br /></div>
<div class="MsoNormal">
Recently, in 2015 identified new protein product
pALTINK4a/b<span style="mso-spacerun: yes;"> </span>which may be responsible for
inducing longevity in these rats. They were able to correlate dependency of
expression of pALTINK4a/b in presence of
high molecular weight HA in mole
rat............................................ This may finding can be
accessed <a href="http://www.pnas.org/content/112/4/1053.full"><i>here</i></a>.</div>
<div class="MsoNormal">
<br /></div>
<div class="MsoNormal">
May be his new finding may help to find newer ways of longer life.</div>
<div class="MsoNormal">
<o:p></o:p></div>
<span style="background-color: white;"><br /></span>
<br />
<br /></div>
<div style="font-size: 12px; line-height: normal;">
<span style="font-family: "helvetica";"></span></div>
Rochhttp://www.blogger.com/profile/10226480566630388819noreply@blogger.com3tag:blogger.com,1999:blog-8173239423928249815.post-9987082238494123912015-10-29T04:06:00.001-07:002015-10-29T04:06:27.411-07:00Important Breakthroughs In Cancer and Ageing<div style="text-align: justify;">
<a href="http://www.oncologybiomarkers.com/2015/10/personalised-cancer-treatment-by.html" target="_blank">Personalised medicine</a> with mTOR inhibitors and Telomerase modulators may serve as important breakthroughs in medicine. May be it can fetch more attention of organisations like<a href="http://www.oncologybiomarkers.com/2015/10/cancer-research-funding-and-major.html" target="_blank"> Cancer Research UK</a>, NCI and other funding agencies help in fighting <b><a href="http://www.agingcell.com/2015/10/ageing-cancer-dependency.html" target="_blank">Cancer and Ageing</a></b> related problems.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
mTOR is nutrition driven pathway. Dietary restrictions causes down regulation of mTORC1 activity. Hence, targeting it with its inhibitor may help in providing anti-ageing and anti-cancer effect as shown in figure below.</div>
<br />
<div class="separator" style="clear: both; text-align: left;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhp0RNXzf0unyolPFqz8jXtcGttAOixsbUyzNa3cDZZVwPyzj309gyrUfroObRFIYJkLRLoMP4ich07AqTUqQPlMt_yk4BOCwvtuS0X1wNaEoDnLMdHAW2DoK0RiWmBjLcsUPqDE76MA0I/s1600/1.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="221" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhp0RNXzf0unyolPFqz8jXtcGttAOixsbUyzNa3cDZZVwPyzj309gyrUfroObRFIYJkLRLoMP4ich07AqTUqQPlMt_yk4BOCwvtuS0X1wNaEoDnLMdHAW2DoK0RiWmBjLcsUPqDE76MA0I/s400/1.png" width="400" /></a></div>
<div class="separator" style="clear: both; text-align: center;">
<br /></div>
<div class="separator" style="clear: both; text-align: justify;">
It shows effect mTORC1 effect on longevity. A cancer cell needs lot of energy because of its increase growing rate. Inhibiting mTORC1 with specific inhibitor helps in providing longevity.</div>
<div class="separator" style="clear: both; text-align: justify;">
<br /></div>
<div class="separator" style="clear: both; text-align: right;">
Scientific paper mTOR and longevity can be accessed from <a href="https://drive.google.com/open?id=0B5HQq5g8ZsuXblVjNEcyZE00cHc" target="_blank"><i>here</i></a></div>
<div class="separator" style="clear: both; text-align: justify;">
<br /></div>
<div class="separator" style="clear: both; text-align: justify;">
According to Peto's paradox, chances of acquiring cancer is more in humans compared to large animals like elephants or whale even though these big sized animals have large number of big sized cells compared to humans.</div>
<div class="separator" style="clear: both; text-align: justify;">
<br /></div>
<div class="separator" style="clear: both; text-align: right;">
Metabolic perspective of Peto's paradox and cancer can be accessed from <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4581028/" target="_blank"><i>here</i></a></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
It's observed that small number of cells divide faster than big sized cells. As a result there are chances to acquire large number of genetic errors in rapidly dividing small cells. And these errors simply keeps on accumulating due to cell division. These accumulation of errors leads development of cancer. Moreover, with every cell division Telomere located at the end of DNA also keeps shortening. So basically with every cell division a piece of information is lost due to DNA damage. Telomerase enzyme helps in prevention of this loss and maintains the Telomere length. This in turn helps in maintaining the original length of DNA and prevents chromosomal shortening.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Details of this basic biology can be visualised in following Youtube video.</div>
<div class="separator" style="clear: both; text-align: justify;">
<iframe allowfullscreen="" class="YOUTUBE-iframe-video" data-thumbnail-src="https://i.ytimg.com/vi/vtXrehpCPEE/0.jpg" frameborder="0" height="266" src="https://www.youtube.com/embed/vtXrehpCPEE?feature=player_embedded" width="320"></iframe>Basic function of telomerase.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Identification molecules which can increase synthesis of telomerase has been of prime importance. These agents can also help in reversing ageing or may be useful for cancer prevention. Understanding of how telomerase works can be seen from a video of famous scientist Prof. Michio Kaku.</div>
<div class="separator" style="clear: both; text-align: justify;">
<iframe allowfullscreen="" class="YOUTUBE-iframe-video" data-thumbnail-src="https://i.ytimg.com/vi/DV3XjqW_xgU/0.jpg" frameborder="0" height="266" src="https://www.youtube.com/embed/DV3XjqW_xgU?feature=player_embedded" width="320"></iframe></div>
<br />
<br />
<br />
<b><br /></b>Rochhttp://www.blogger.com/profile/10226480566630388819noreply@blogger.com6tag:blogger.com,1999:blog-8173239423928249815.post-21797324635064980502015-10-23T21:47:00.005-07:002015-10-23T21:55:30.742-07:00Ageing-Cancer dependencyCancer is basically defined as uncontrolled multiplication of cells. On the other hand, a<span style="font-family: inherit;">geing is characterised by a progressive loss of physiological integrity, leading to impaired function and increased vulnerability to death.</span><br />
<span style="color: #6a6a6a; font-family: inherit;"><b><br /></b></span>
<span style="font-family: inherit;">Cancer is one of the age related disease.<span style="color: #6aa84f;"> The chances of </span></span><span style="color: #6aa84f;">occurrence<span style="font-family: inherit;"> increases with age as reported by Cancer Research UK, Centre for Disease Control (CDC) given graphs below</span></span><br />
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiCXLKm_2nI8HXwGTBtzXIgJYTa3UVUb-lNoaBuNFEhpeNrgpPnbJ37rn31410F9IUYd9vCNAPuy6GWUjsG-Mnym-k3uxyk5rYyJPkfLc3ERZmtNZgpAl0ODEWs4Le9At72mnTu8RTUDdg/s1600/1.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="222" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiCXLKm_2nI8HXwGTBtzXIgJYTa3UVUb-lNoaBuNFEhpeNrgpPnbJ37rn31410F9IUYd9vCNAPuy6GWUjsG-Mnym-k3uxyk5rYyJPkfLc3ERZmtNZgpAl0ODEWs4Le9At72mnTu8RTUDdg/s400/1.png" width="400" /></a><b>For more info click</b> <i><a href="http://cancer research agency vancouver">here</a></i></div>
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEh0b1IbCYJ0q8t54QZIlhJBawh_aGQgaUlIB-a9taWBtU3MMV7vT3HXOXVkjCbAuNCo0ZQVfcS3y80maL3_KnIs1Wf32qeKAbUYxc0X0K4xWM5PuEXwvM8s61-6JiPUBwXHxGqoJxO20As/s1600/2.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="308" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEh0b1IbCYJ0q8t54QZIlhJBawh_aGQgaUlIB-a9taWBtU3MMV7vT3HXOXVkjCbAuNCo0ZQVfcS3y80maL3_KnIs1Wf32qeKAbUYxc0X0K4xWM5PuEXwvM8s61-6JiPUBwXHxGqoJxO20As/s400/2.png" width="400" /></a><b>For more info click</b> <i><a href="https://nccd.cdc.gov/uscs/cancersbyraceandethnicity.aspx">here</a></i></div>
<span style="background-color: white; color: #545454;"><span style="font-family: inherit;"><br /></span></span><span style="background-color: white; color: #545454; font-family: inherit;">These tables clearly shows relation of ageing and cancer in clinical scenario. </span><br />
<br />
<span style="background-color: white; color: #545454; font-family: inherit;"><b>At cellular level </b>r</span><span style="background-color: white; color: #545454; font-family: inherit;">elation of cancer and ageing can be visualised from the following image. As we know that cells in cancer condition grows faster hence they also catch up to the ultimate fate of death faster as compared to normal tissue. </span><br />
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjVAexa-uR9MYtWpDuhnSxWAUuZYUKt-MiuSIHiFiiRVAe-iDdsavD6J8VrnQDsY8IIw8YgqbDuJiW66KUmiOYTA9SElvAR_hrHaDNIOekcO0pBiBC5_xK_6FOtoiRCW78lk7zNSqwH8kU/s1600/nature05985-f1.2.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="243" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjVAexa-uR9MYtWpDuhnSxWAUuZYUKt-MiuSIHiFiiRVAe-iDdsavD6J8VrnQDsY8IIw8YgqbDuJiW66KUmiOYTA9SElvAR_hrHaDNIOekcO0pBiBC5_xK_6FOtoiRCW78lk7zNSqwH8kU/s400/nature05985-f1.2.jpg" width="400" /></a></div>
<div class="separator" style="clear: both; text-align: right;">
<br /></div>
<div class="separator" style="clear: both; text-align: right;">
<b><br /></b></div>
<div class="separator" style="clear: both; text-align: left;">
<!--[if gte mso 9]><xml>
<o:DocumentProperties>
<o:Revision>0</o:Revision>
<o:TotalTime>0</o:TotalTime>
<o:Pages>1</o:Pages>
<o:Words>114</o:Words>
<o:Characters>655</o:Characters>
<o:Company>BioNano </o:Company>
<o:Lines>5</o:Lines>
<o:Paragraphs>1</o:Paragraphs>
<o:CharactersWithSpaces>768</o:CharactersWithSpaces>
<o:Version>14.0</o:Version>
</o:DocumentProperties>
<o:OfficeDocumentSettings>
<o:AllowPNG/>
</o:OfficeDocumentSettings>
</xml><![endif]-->
<!--[if gte mso 9]><xml>
<w:WordDocument>
<w:View>Normal</w:View>
<w:Zoom>0</w:Zoom>
<w:TrackMoves/>
<w:TrackFormatting/>
<w:PunctuationKerning/>
<w:ValidateAgainstSchemas/>
<w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
<w:IgnoreMixedContent>false</w:IgnoreMixedContent>
<w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
<w:DoNotPromoteQF/>
<w:LidThemeOther>EN-US</w:LidThemeOther>
<w:LidThemeAsian>JA</w:LidThemeAsian>
<w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>
<w:Compatibility>
<w:BreakWrappedTables/>
<w:SnapToGridInCell/>
<w:WrapTextWithPunct/>
<w:UseAsianBreakRules/>
<w:DontGrowAutofit/>
<w:SplitPgBreakAndParaMark/>
<w:EnableOpenTypeKerning/>
<w:DontFlipMirrorIndents/>
<w:OverrideTableStyleHps/>
<w:UseFELayout/>
</w:Compatibility>
<m:mathPr>
<m:mathFont m:val="Cambria Math"/>
<m:brkBin m:val="before"/>
<m:brkBinSub m:val="--"/>
<m:smallFrac m:val="off"/>
<m:dispDef/>
<m:lMargin m:val="0"/>
<m:rMargin m:val="0"/>
<m:defJc m:val="centerGroup"/>
<m:wrapIndent m:val="1440"/>
<m:intLim m:val="subSup"/>
<m:naryLim m:val="undOvr"/>
</m:mathPr></w:WordDocument>
</xml><![endif]--><!--[if gte mso 9]><xml>
<w:LatentStyles DefLockedState="false" DefUnhideWhenUsed="true"
DefSemiHidden="true" DefQFormat="false" DefPriority="99"
LatentStyleCount="276">
<w:LsdException Locked="false" Priority="0" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Normal"/>
<w:LsdException Locked="false" Priority="9" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="heading 1"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 2"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 3"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 4"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 5"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 6"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 7"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 8"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 9"/>
<w:LsdException Locked="false" Priority="39" Name="toc 1"/>
<w:LsdException Locked="false" Priority="39" Name="toc 2"/>
<w:LsdException Locked="false" Priority="39" Name="toc 3"/>
<w:LsdException Locked="false" Priority="39" Name="toc 4"/>
<w:LsdException Locked="false" Priority="39" Name="toc 5"/>
<w:LsdException Locked="false" Priority="39" Name="toc 6"/>
<w:LsdException Locked="false" Priority="39" Name="toc 7"/>
<w:LsdException Locked="false" Priority="39" Name="toc 8"/>
<w:LsdException Locked="false" Priority="39" Name="toc 9"/>
<w:LsdException Locked="false" Priority="35" QFormat="true" Name="caption"/>
<w:LsdException Locked="false" Priority="10" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Title"/>
<w:LsdException Locked="false" Priority="1" Name="Default Paragraph Font"/>
<w:LsdException Locked="false" Priority="11" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Subtitle"/>
<w:LsdException Locked="false" Priority="22" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Strong"/>
<w:LsdException Locked="false" Priority="20" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Emphasis"/>
<w:LsdException Locked="false" Priority="59" SemiHidden="false"
UnhideWhenUsed="false" Name="Table Grid"/>
<w:LsdException Locked="false" UnhideWhenUsed="false" Name="Placeholder Text"/>
<w:LsdException Locked="false" Priority="1" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="No Spacing"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 1"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 1"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 1"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 1"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 1"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 1"/>
<w:LsdException Locked="false" UnhideWhenUsed="false" Name="Revision"/>
<w:LsdException Locked="false" Priority="34" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="List Paragraph"/>
<w:LsdException Locked="false" Priority="29" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Quote"/>
<w:LsdException Locked="false" Priority="30" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Intense Quote"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 1"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 1"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 1"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 1"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 1"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 1"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 1"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 1"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 2"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 2"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 2"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 2"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 2"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 2"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 2"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 2"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 2"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 2"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 2"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 2"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 2"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 2"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 3"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 3"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 3"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 3"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 3"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 3"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 3"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 3"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 3"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 3"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 3"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 3"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 3"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 3"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 4"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 4"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 4"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 4"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 4"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 4"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 4"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 4"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 4"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 4"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 4"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 4"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 4"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 4"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 5"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 5"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 5"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 5"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 5"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 5"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 5"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 5"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 5"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 5"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 5"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 5"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 5"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 5"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 6"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 6"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 6"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 6"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 6"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 6"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 6"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 6"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 6"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 6"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 6"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 6"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 6"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 6"/>
<w:LsdException Locked="false" Priority="19" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Subtle Emphasis"/>
<w:LsdException Locked="false" Priority="21" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Intense Emphasis"/>
<w:LsdException Locked="false" Priority="31" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Subtle Reference"/>
<w:LsdException Locked="false" Priority="32" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Intense Reference"/>
<w:LsdException Locked="false" Priority="33" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Book Title"/>
<w:LsdException Locked="false" Priority="37" Name="Bibliography"/>
<w:LsdException Locked="false" Priority="39" QFormat="true" Name="TOC Heading"/>
</w:LatentStyles>
</xml><![endif]-->
<!--[if gte mso 10]>
<style>
/* Style Definitions */
table.MsoNormalTable
{mso-style-name:"Table Normal";
mso-tstyle-rowband-size:0;
mso-tstyle-colband-size:0;
mso-style-noshow:yes;
mso-style-priority:99;
mso-style-parent:"";
mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
mso-para-margin:0cm;
mso-para-margin-bottom:.0001pt;
mso-pagination:widow-orphan;
font-size:12.0pt;
font-family:"Times New Roman";}
</style>
<![endif]-->
<!--StartFragment-->
<!--EndFragment--></div>
<div class="MsoNormal">
During normal ageing, stem cells accumulate damage and
subsequent stress-dependent changes (for example, de-repression of the
CDKN2a(INK4a/ARF) locus or telomere shortening). This leads to the increasing
abundance of senescent cells (large blue cells) within differentiated tissues.
Incipient tumours, arising directly from stem cells or from more committed
cells, undergo rapid proliferation (small red cells). These pre-malignant
tumour cells rapidly accumulate damage, in part owing to the presence of oncogenes,
leading to a higher proportion of tumour cells becoming senescent (small blue
cells). Tumour progression to full malignancy is favoured when tumour cells
acquire mutations that impair the senescence program (for example, mutations in
Trp53 or CDKN2a).<o:p></o:p></div>
<div class="MsoNormal">
<br /></div>
<div class="separator" style="clear: both; text-align: right;">
<b>Biology of ageing-cancer relation is accessible</b> <i><a href="http://www.nature.com/nature/journal/v448/n7155/full/nature05985.html">here</a></i></div>
<div class="separator" style="clear: both; text-align: left;">
<br /></div>
<div class="separator" style="clear: both; text-align: left;">
Most commonly explored pathway for the treatment of ageing and at the same time cancer is m-TOR. I believe it is a wonder pathway for treatment of variety of other age related diseases. </div>
<div class="separator" style="clear: both; text-align: left;">
<br /></div>
<div class="separator" style="clear: both; text-align: left;">
Moreover, this pathway serve as link between cancer and ageing. So inhibiting m-TOR not only stops cancer multiplication but also helps in increasing life expectancy of cells. It is ironical to say that inhibition of m-TOR helps in inhibiting two different ends of life viz. cancer (symbolises uncontrolled cell division) and ageing (symbolises death). </div>
<div class="separator" style="clear: both; text-align: left;">
<br /></div>
<div class="separator" style="clear: both; text-align: right;">
<b>Scientific paper for correlation of mTOR with age related disease can be downloaded from </b><i><a href="http://www.nature.com/nature/journal/v493/n7432/full/nature11861.html">here</a></i></div>
<div class="separator" style="clear: both; text-align: right;">
<br /></div>
<div class="separator" style="clear: both; text-align: left;">
Hence, <a href="http://www.oncologybiomarkers.com/2015/10/personalised-cancer-treatment-by.html">personalised cancer medicine</a> by Pathway Pharmaceuticals and Insilco Inc. will help in developing newer strategies of increasing the life expectancy of not only cancer patients but also other individuals suffering from age related diseases.</div>
Rochhttp://www.blogger.com/profile/10226480566630388819noreply@blogger.com15tag:blogger.com,1999:blog-8173239423928249815.post-76323758091458855982015-05-04T20:50:00.001-07:002015-05-05T06:25:45.227-07:00Insilico Medicine SuperPharman Challenge: Looking for Superheroes to Transform Big Pharma <h2 style="background-color: white; color: #222222; font-family: arial, sans-serif; font-size: 13.333333969116211px; text-align: center;">
<span style="font-family: Arial;"><b>New Super Jobs @ Insilico Medicine Announced</b></span></h2>
<div style="background-color: white; color: #222222; font-family: arial, sans-serif; font-size: 13.333333969116211px;">
<span style="font-family: Arial;"><br /></span></div>
<div style="background-color: white; color: #222222; font-family: arial, sans-serif; font-size: 13.333333969116211px;">
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgbooicuErKiIecswcLAHVsnRcuuYmdQTTPUS4WnRGEryOeuOe_QSJurI4JaUQfU3cPKrN99bExDmea4j2PN0WJf9soLBkkdSWLyotc5FcwZTM2UGayFf8kzLxhC2wbzv67w36FWvPEjbc/s1600/TransPharman1+-+Leader.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="320" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgbooicuErKiIecswcLAHVsnRcuuYmdQTTPUS4WnRGEryOeuOe_QSJurI4JaUQfU3cPKrN99bExDmea4j2PN0WJf9soLBkkdSWLyotc5FcwZTM2UGayFf8kzLxhC2wbzv67w36FWvPEjbc/s320/TransPharman1+-+Leader.jpg" width="320" /></a></div>
<div class="separator" style="clear: both; text-align: center;">
<br /></div>
<span style="font-family: Arial;">Aging fighters at Insilico Medicine are looking for relentless doers who dream big, but are not afraid to get their hands dirty with basic tasks. Doers, who have trouble sleeping at night, because they know that millions of people are suffering and dying of cancer and age-related diseases and their own clock is ticking as well. Doers with both programming and database management skills and knowledge of biology. You will need to know or quickly learn how to use huge multi-omics data to find alternative uses of currently available drugs and distribute many micro tasks to the crowd, freelancers or colleagues, while keeping the big picture in mind. </span><br />
<span style="font-family: Arial;"></span><br />
<span style="font-family: Arial;">We know that we are looking for a needle in the haystack, but this is how our team has come to be and you will be in great company. We have relentless super heroes in the US, UK, Switzerland, Poland, Israel, Russia and China. If you know someone amazing, who fits that profile amazing, ask him. Maybe he or she is already working for us. He goes through the day doing a boring academic job, but at night he is hacking away.</span><br />
<br />
<span style="font-family: Arial;">Our first frontier is transforming the pharmaceutical industry, repurposing known drugs and finding the new ones. When we launch, the world will become a better place. And if you are that super hero with bold ideas and hands on experience, ready to unleash maniacal energy to hack aging, send us a signal and we will respond right away or start watching you to see if you fit.</span></div>
<div style="background-color: white; color: #222222; font-family: arial, sans-serif; font-size: 13.333333969116211px;">
<span style="font-family: Arial; font-size: x-small;"><br /></span></div>
<div style="background-color: white;">
<span style="color: #222222; font-family: Arial; font-size: x-small;">Here is a link to what Insilico Medicine is doing: </span></div>
<div style="background-color: white;">
<span style="color: #222222; font-family: Arial; font-size: x-small;"><br /></span></div>
<div class="separator" style="clear: both; text-align: center;">
<iframe allowfullscreen="" class="YOUTUBE-iframe-video" data-thumbnail-src="https://i.ytimg.com/vi/hWUqZmDBJLc/0.jpg" frameborder="0" height="266" src="https://www.youtube.com/embed/hWUqZmDBJLc?feature=player_embedded" width="320"></iframe></div>
<div style="background-color: white;">
<span style="background-color: transparent;"><br /></span></div>
<div style="background-color: white; color: #222222; font-family: arial, sans-serif; font-size: 13.333333969116211px;">
<span style="font-family: Arial; font-size: x-small;">In partnerships they can also do in vitro and in vivo validation, humouse clinical trials and even organ-on-a-chip and body-on-a-chip validation. </span><span style="font-family: Arial;"></span><br />
<span style="font-family: Arial;">They are looking for someone with similar skill set and energy as Alex Zhavoronkov (<a href="http://www.linkedin.com/in/zhavoronkov" style="color: #1155cc;" target="_blank"><span style="color: #042eee;"><u>www.linkedin.com/in/<wbr></wbr>zhavoronkov</u></span></a>) to work together with him, gradually replace him and then find someone to replace yourself as the company grows or you decide to start a subsidiary. </span><br />
<span style="font-family: Arial;"></span><br />
<span style="font-family: Arial;"><b>Minimum requirements:</b></span><br />
<ul>
<li><span style="font-family: Arial; font-size: 13.333333969116211px;">Python, MySQL, Hadoop, AWS Services, IBM Watson</span></li>
<li><span style="font-family: Arial; font-size: 13.333333969116211px;">Experience working with multi-omics data and/or clinical trials/biomedical text data</span></li>
<li><span style="font-family: Arial; font-size: 13.333333969116211px;">SVM and deep learning algorithms</span></li>
<li><span style="font-family: Arial; font-size: 13.333333969116211px;">Basic knowledge of signaling and metabolic pathways</span></li>
<li><span style="font-family: Arial; font-size: 13.333333969116211px;">Experience working with GEO, ArrayExpress, KEGG, TCGA, LINCS, Connectivity Map, Drugbank, Clinical Trials, WHO databases, etc.</span></li>
<li><span style="font-family: Arial; font-size: 13.333333969116211px;">Personal network of contacts in academia and large pharmaceutical companies</span></li>
<li><span style="font-family: Arial; font-size: 13.333333969116211px;">Excellent writing skills</span></li>
<li><span style="font-family: Arial; font-size: x-small;">Ability to give public talks and generate publicity is a plus</span></li>
<li><span style="font-family: Arial; font-size: 13.333333969116211px;">Knowledge of Russian, Chinese or Hebrew is a plus</span></li>
</ul>
</div>
<br />
<div>
<br /></div>
<div>
<br /></div>
<div>
<br /></div>
<div>
<br /></div>
Unknownnoreply@blogger.com2tag:blogger.com,1999:blog-8173239423928249815.post-74195712902595082582015-01-04T02:46:00.001-08:002015-01-04T02:46:44.493-08:00Featured conference on the future of longevityPlease consider attending this notable conference: <a href="http://www.chathamhouse.org/conferences/ageing" target="_blank">Ageing and Health: Policy and Economics in an Era of Longevity</a><br />
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgI5Gt5NJJFtCYypEu9mHuuZXZWNBwpWhOHdiSDXnjgHIDqi-G5UUVp3_yJpZ0pDDZLweumhtfliuRpSNGRdU3rEtSrOpqey4p6uGtRRUcm58DvOrRWHyi4mVN9lOHF8bQhoCZ8s6ONvOk/s1600/Chatham+Event+Banner.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgI5Gt5NJJFtCYypEu9mHuuZXZWNBwpWhOHdiSDXnjgHIDqi-G5UUVp3_yJpZ0pDDZLweumhtfliuRpSNGRdU3rEtSrOpqey4p6uGtRRUcm58DvOrRWHyi4mVN9lOHF8bQhoCZ8s6ONvOk/s1600/Chatham+Event+Banner.jpg" height="79" width="640" /></a></div>
<br />Unknownnoreply@blogger.com2tag:blogger.com,1999:blog-8173239423928249815.post-63345196611326366662014-10-03T04:18:00.001-07:002014-10-03T04:18:33.109-07:00Everyday drugs could give extra years of life - New ScientistGreat article on New Scientist by the talented science journalist Clare Wilson covering the Aging Forum.<br /><br />
<br /><br />
<a href="http://www.newscientist.com/article/mg22429894.000-everyday-drugs-could-give-extra-years-of-life.html#.VC6FS5Gf1-f.blogger">Everyday drugs could give extra years of life - health - 01 October 2014 - New Scientist</a>Unknownnoreply@blogger.com2tag:blogger.com,1999:blog-8173239423928249815.post-26051974625036667512014-03-05T16:34:00.001-08:002014-03-05T16:55:06.923-08:00Calico, Human Longevity Inc, etc. What are the possible strategies for aging drug development?<div dir="ltr" style="line-height: 1.15; margin-bottom: 0pt; margin-top: 0pt;">
<span font-family: 'Times New Roman'; font-size: 16px; line-height: 1.15; white-space: pre-wrap;">Aging is one of the major challenges of the modern society. The advances in biomedicine and healthcare systems have led to the unprecedented long lives of the population after the retirement leading to the increased burden on the economies. There is an urgent need to develop and validate interventions with geroprotective properties to increase the productive health spans of the working population and maintaining performance and avoiding loss of function.</span></div>
<div dir="ltr" style="line-height: 1.15; margin-bottom: 0pt; margin-top: 12pt;">
<span color: black; font-family: 'Times New Roman'; font-size: 16px; font-style: normal; font-variant: normal; font-weight: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;">Experiments with animal models already resulted in significant breakthroughs resulting in up to 1,000 percent increases in lifespans. But extrapolating these advances to humans or other mammals proved to be extremely challenging. Human live orders of magnitude longer than the short-lived model organisms and there is no comprehensive set of aging biomarkers, allowing to track the effects of the many drugs that may extend lifespan. We are also different from other animals and the many drugs that work on mice do not work on humans. </span></div>
<div dir="ltr" style="line-height: 1.15; margin-bottom: 0pt; margin-top: 12pt;">
<span color: black; font-family: 'Times New Roman'; font-size: 16px; font-style: normal; font-variant: normal; font-weight: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;">To address these challenges the international team comprised of biogerontologists, geneticists, computer scientists and biomathematicians proposed using a computer simulation and laboratory validation approach using human cells and model organisms to predict what drugs may help fight aging in humans. </span></div>
<div dir="ltr" style="line-height: 1.15; margin-bottom: 0pt; margin-top: 12pt;">
<span color: black; font-family: 'Times New Roman'; font-size: 16px; font-style: normal; font-variant: normal; font-weight: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;">The Human Genome Project and the following revolution in sequencing and laboratory diagnostics resulted in the vast data on genetic and epigenetic profiles of cells and tissues from people of various ages. The proposed method uses this data to construct the cloud of molecular signalling pathways involved in aging and longevity and evaluates the effects of the very large number of drugs and drug combinations to simulate the young state of the cells and tissues. Scientists hope that this method may be used to find new drugs with aging-suppressive properties and predict the activity of the drugs that are already on the market. Also, people respond to the drugs differently and this method may be able to personalize the geroprotective therapy to the individual patients and help the drug companies conduct better clinical trials. </span></div>
<div dir="ltr" style="line-height: 1.15; margin-bottom: 0pt; margin-top: 12pt;">
<span color: black; font-family: 'Times New Roman'; font-size: 16px; font-style: normal; font-variant: normal; font-weight: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;">"There are thousands of compounds with known molecular targets and some are already used in the clinic. Due to high cost and the time it takes to complete the experimental work, it may not be possible to test all of the effects of these drugs even in mice. And the fact that the drug works in mice does not guarantee the same effect in humans. There needs to be a better way to predict the efficacy of the drug in humans. We proposed a method for doing that in silico using the multiple sources of data and we hope to validate this method in the very near future.", said Alex Zhavoronkov, PhD, the director of the Biogerontology Research Foundation in the UK. "Also, people are different, age at different rates and respond to drugs differently. The proposed method may be used to predict the personalized geroprotector regiments.", he added. </span></div>
<div dir="ltr" style="line-height: 1.15; margin-bottom: 0pt; margin-top: 12pt;">
<span color: black; font-family: 'Times New Roman'; font-size: 16px; font-style: normal; font-variant: normal; font-weight: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;">Many pharmaceutical companies already expressed their interest in bringing aging research into clinical practice, but the absence of the business models, accurate validation methods, and the inability to classify aging as the curable disease are major impediments to mainstream development of geroprotective drugs. In silico drug discovery may help accelerate this process. The group plans to present the results of their experimental work using this method at the Practical Applications of Aging Research Symposium at MipTek 2014 in Basel, Switzerland attended by over 3,000 delegates from the pharmaceutical industry. </span></div>
<div dir="ltr" style="line-height: 1.15; margin-bottom: 0pt; margin-top: 12pt;">
<span color: black; font-family: 'Times New Roman'; font-size: 16px; font-style: normal; font-variant: normal; font-weight: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;">“The decreases in cost and increased availability of genetic and epigenetic research as well as the breakthroughs in computer technologies are already helping make better decisions in biomedicine. The proposed method may take the in silico approach to drug discovery to the next level. If the can validate it in the laboratory, and we are working on that as we speak, this may revolutionize aging research”, said Anton Buzdin, the director of the First Oncology Research and Advisory Center.</span></div>
<span ><b id="docs-internal-guid-c2113a78-94d1-48f1-c192-f224de6d5490" style="font-weight: normal;"><br /><span style="color: black; font-family: 'Times New Roman'; font-size: 16px; font-style: normal; font-variant: normal; font-weight: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;"></span></b>
</span><br />
<div dir="ltr" style="line-height: 1.15; margin-bottom: 0pt; margin-top: 0pt;">
<span ><a href="http://journal.frontiersin.org/Journal/10.3389/fgene.2014.00049/abstract" style="text-decoration: none;"><span style="color: #1155cc; font-family: 'Times New Roman'; font-size: 16px; font-style: normal; font-variant: normal; font-weight: normal; text-decoration: underline; vertical-align: baseline; white-space: pre-wrap;">The paper</span></a><span style="color: black; font-family: 'Times New Roman'; font-size: 16px; font-style: normal; font-variant: normal; font-weight: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;"> describing the new approach to screening and ranking of geroprotective drugs was published in the reputable scientific journal </span><a href="http://journal.frontiersin.org/" style="text-decoration: none;"><span style="color: #1155cc; font-family: 'Times New Roman'; font-size: 16px; font-style: normal; font-variant: normal; font-weight: normal; text-decoration: underline; vertical-align: baseline; white-space: pre-wrap;">Frontiers in Genetics</span></a><span style="color: black; font-family: 'Times New Roman'; font-size: 16px; font-style: normal; font-variant: normal; font-weight: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;">. </span></span></div>
<span ><br />
<span style="font-family: 'Times New Roman'; font-size: 16px; vertical-align: baseline; white-space: pre-wrap;"></span><br />
</span><br />
<div dir="ltr" style="line-height: 1.15; margin-bottom: 0pt; margin-top: 0pt;">
<span ><span style="color: black; font-family: 'Times New Roman'; font-size: 16px; font-style: normal; font-variant: normal; font-weight: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;">Citation: Zhavoronkov A, Buzdin AA, Garazha AV, Borissoff N and Moskalev AA (2014). Signaling pathway cloud regulation for in silico screening and ranking of the potential geroprotective drugs. Front. Genet. 5:49. doi: 10.3389/fgene.2014.00049 - See more at: </span><a href="http://journal.frontiersin.org/Journal/10.3389/fgene.2014.00049/abstract#sthash.2qpLbytY.dpuf" style="text-decoration: none;"><span style="color: #1155cc; font-family: 'Times New Roman'; font-size: 16px; font-style: normal; font-variant: normal; font-weight: normal; text-decoration: underline; vertical-align: baseline; white-space: pre-wrap;">http://journal.frontiersin.org/Journal/10.3389/fgene.2014.00049/abstract#sthash.2qpLbytY.dpuf</span></a><span style="color: black; font-family: 'Times New Roman'; font-size: 16px; font-style: normal; font-variant: normal; font-weight: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;"></span></span></div>
<span ><br />
<br />
<a href="http://www.frontiersin.org/Journal/10.3389/fgene.2014.00049/full#sthash.5Ln1dVoI.cmfs">Signaling pathway cloud regulation for in silico screening and ranking of the potential geroprote...</a></span>Unknownnoreply@blogger.com2tag:blogger.com,1999:blog-8173239423928249815.post-87681748299502081712013-10-21T16:27:00.002-07:002013-10-21T16:27:23.564-07:00www.LabFairy.com - One young scientist's quest to defeating aging<br />
It is always a pleasure to see the young scientists working on their projects with passion and dedication. It is even a greater pleasure to see some of the outstanding ones trying to popularize research in their field. Maria Litovchenko, a young scientist, who recently graduated from the Moscow Institute of Physics and Technology and is doing her graduate work at LMU Muenschen is running an excellent blog – <a href="http://www.labfairy.com/" target="_blank">Laboratory Fairy (www.LabFairy.com) </a>. It is a pleasure to see someone truly dedicated to defeating aging through excellence in scientific research.<br />
<br />
We would like to wish her all the best in her endeavors.<br />
Unknownnoreply@blogger.com1tag:blogger.com,1999:blog-8173239423928249815.post-59265747000141781712013-10-01T12:05:00.001-07:002013-10-01T12:05:11.236-07:00<div class="rpuEmbedCode">
<div class="rpuArticle rpuRepost-a3da69b958eb57bc2f60d5d7472b3720-top" style="margin:0;padding:0;">
<script src="https://1.rp-api.com/rjs/repost-article.js?3" type="text/javascript" data-cfasync="false"></script><a href="http://s.tt/1MLAU" class="rpuThumb" rel="norewrite"><img src="//img.1.rp-api.com/thumb/7572750" style="float:left;margin-right:10px;" /></a><a href="http://s.tt/1MLAU" class="rpuTitle" rel="norewrite"><strong>Aging Expert Urges Government Leaders to Accelerate Research in Aging and Proactively Increase the Retirement Age to Prevent Economic Crisis</strong></a> (via <a href="http://s.tt/1MLAU" class="rpuHost" rel="norewrite">SBWire</a>)<p class="rpuSnip">
Forest Hills, NY -- (SBWIRE) -- 10/01/2013 -- A leading expert on aging sees extending healthy lifespan as the most plausible solution and a source of growth for the debt-laden faltering economies of the developed countries. In his newly released book…
</p>
</div>
</div><!-- put the "tease", "jump" or "more" break here --><hr id="system-readmore" style="display: none;" /><a name='more'></a><!--break--><hr class="at-page-break" style="display: none;"/><div class="rpuEmbedCode">
<div class="rpuArticle rpuRepostMain rpuRepost-a3da69b958eb57bc2f60d5d7472b3720-bottom" style="display:none;"> </div>
<div style="display: none;"><!-- How to customize this embed: http://www.repost.us/article-preview/hash/4760a3e159310c29ac236999fa1c6ad9 --></div>
</div>Unknownnoreply@blogger.com0